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 For most bacterial pathogens, adherence of the bacterium to the surface 
of the host cell tissue is a necessary first step for colonization and infection.  
Agents that inhibit adherence, therefore, could be useful for preventing infections.  
The goal of this research was to assess the anti-adherent activity of several food-
grade prebiotic carbohydrates, plant extracts, and other naturally-derived 
molecules against enteric pathogens. First, the antiadherent effect of 
galactooligosaccharides (GOS), polydextrose (PDX), and a GOS-PDX blend was 
tested against two strains of Cronobacter “Enterobacter” sakazakii. When 
measured microscopically or by cultural methods, significant reductions in 
adherence (56% and 71%, respectively) of C. sakazakii were observed in the 
presence of GOS (16 mg/ml).  Adherence inhibition also occurred (48%) when 
the GOS-PDX blend (8 mg/ml each) was tested, although PDX by itself had less 
ii 
 
effect. Subsequently, the ability of several prebiotic agents, including 
chitooligosaccharides (COS) and mannan oligosaccharides derived from yeast 
cell walls (MOSy) and konjac root (MOSk), to inhibit adherence of 
enteropathogenic Escherichia coli (EPEC), enterohemorragic Escherichia coli 
(EHEC) and Salmonella typhimurium to a human HEp-2 cell line was tested.  In 
addition, a high molecular weight component of cranberry (CHMW) was also 
assessed for anti-adherence.  Different fractions of COS significantly reduced 
adherence of EPEC at a concentration of 16 mg/ml.  Although MOSy inhibited 
EPEC, EHEC, and S. typhumiurim, adherence inhibition was not observed for 
MOSk.  Adherence inhibition of EPEC, EHEC, and S. typhumiurim by CHMW 
was observed. Finally, the ability of two different types of lactoferrin to inhibit 
adherence of Cronobacter sakazakii to a HEp-2 human cell line was assessed. 
Results showed that the adherence of C. sakazakii was significantly reduced at a 
minimum concentration of 10 mg/ml.  However, at higher concentrations (up to 
50 mg/ml), further reductions in adherence were not observed. These results 
show that different prebiotics, plant extracts, and other molecules may be added 
to foods as a prophylactic treatment to prevent or mitigate infections by enteric 
pathogens.  
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Preface 
This thesis is comprised of five chapters. Chapter 1 provides a review of 
the current literature on the anti-adherent effect of different prebiotic 
oligosaccharides and plant extracts. Chapter 2 describes our published (Quintero 
et al. 2011 Current Microbiology) results focusing on the antiadhesive effect of 
galactooligosaccharides (GOS) and polydextrose (PDX), alone and in 
combination, against Cronobacter sakazakii. Chapter 3 describes the results 
obtained when testing the antiadherent effect of different prebiotic 
oligosaccharides and plant extracts against EPEC, EHEC, and Salmonella 
typhimurium. Chapter 4 describes results on the antiadherent effect of lactoferrin 
against Cronobacter sakazakii at different doses. Finally, Chapter 5 provides a 
conclusion section that summarizes the major research findings presented within 
this thesis. 
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Chapter 1 
Prebiotic Oligosaccharides, Plant Extracts, and Naturally Derived 
Molecules: A review on Their Beneficial Effects and Anti-adherent Activity 
Against Pathogens  
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Introduction 
 Prebiotics are a group of dietary components that have received 
considerable attention due to their ability to modulate the gastrointestinal 
microbiota and confer health benefits to the host.  Prebiotics were initially defined 
in rather narrow terms as “non-digestible food ingredients that provide a 
beneficial effect to the host by stimulating the growth of selected members of the 
gastrointestinal tract, and thus improve host health”’(Gibson et al. 1995).  More 
recently, prebiotics were redefined as “selectively fermented ingredient(s) that 
allows specific changes, both in the composition and/or activity in the 
gastrointestinal microflora, that confers benefits upon host well-being and health 
(Roberfroid 2007).  However, by either definition, food ingredients have been 
considered as prebiotics based exclusively on their ability to cause changes in 
the intestinal microbiota. 
 Among the food components considered as prebiotics, most are 
comprised of soluble oligosaccharides and polysaccharides.  Some dietary fibers 
have also been suggested as having prebiotic characteristics, although not all of 
them fulfill the requirements to be classified as prebiotic (Roberfroid 2007). To 
avoid claims that are not fully supported, Roberfroid suggested that a food 
ingredient can be classified as a prebiotic if: i) it is not hydrolyzed, nor absorbed 
in the upper part of the gastrointestinal tract, ii) it is a selective substrate for 
beneficial members of the gastrointestinal tract, which will be stimulated to grow 
or be metabolically activated, iii) it is able to alter the intestinal microflora in favor 
of a healthier composition, and iv) it is able to induce systemic effects that are 
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beneficial to host health (Gibson et al. 1995; Roberfroid 1993; Roberfroid 1998).  
Non-digestible oligosaccharides such as inulin, galactooligosaccharides (GOS), 
and fructooligosaccharides (FOS) are now well established as prebiotics; 
however, more research is needed to determine whether xylooligosaccharides, 
soybean oligosaccharides, and glucooligosaccharides, should be regarded as 
prebiotics (Roberfroid 2007; Gibson et al. 2004; Roberfroid 2000). 
 Despite the criteria described above, studies have been reported in recent 
years that indicate prebiotics may enhance host health not only by shifting the 
gut microbiota but by an entirely different biological function.  Specifically, several 
research groups have shown that prebiotics may directly prevent infections by 
inhibiting the ability of pathogenic bacteria to adhere to target tissues in the host 
(Shoaf et al. 2006; Gibson et al. 2005; Saulnier et al. 2009).  In this chapter, the 
bifidogenic health benefits of prebiotics will be briefly reviewed, but particular 
attention will be devoted to their antiadherence activities and the proposed model 
by which prebiotics can be used to inhibit foodborne infections.  Additionally, the 
antiadherent activity of novel prebiotic oligosaccharides and plant extracts will be 
addressed. 
Prebiotics, oligosaccharides, and human health 
Among the most well studied prebiotics are inulin, FOS, and GOS.  They 
are either extracted from natural sources (e.g., inulin from chicory root), produced 
via hydrolysis of plant polysaccharides (e.g., FOS from inulin) or synthesized 
enzymatically from sugars found in milk or plant material (e.g., FOS and GOS 
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from sucrose and lactose, respectively) via glycosyl transferase reactions 
(Grizard & Barthomeuf 1999; L'Hocine 2000). Interestingly, human milk and 
colostrum from lactating animals also contain high concentrations (> 1%) of 
oligosaccharides (Coppa et al. 2008) that have prebiotic activity. 
 That these two groups of oligosaccharides (i.e., those that are food grade 
and those are obtained from human milk) have general structural similarities has 
led to the suggestion that they may also share similar biological activities.  It is 
well known that human milk is already a very rich source of nutrients, including 
oligosaccharides that are important for the health of the infant during the first few 
months of life (Coppa et al. 2006).  This oligosaccharides fraction, which can 
reach concentrations as high as 8 to 12 g/L (Kunz et al. 2000), is comprised of 
sialic acid, N-acetylglucosamine, L-fucose, D-glucose, and D-galactose.  
Galactose residues form three different types of oligosaccharides found in human 
milk: 3’-galactosyl-lactose, 4’galactosyl-lactose, and 6’-galactosyl-lactose 
(Boehm et al. 2005; Torres et al. 2010).  The absence of fucose and amine 
groups in commercial GOS products distinguishes these OS from human milk 
OS and has led some researchers to argue that these structural differences “do 
not support a direct parallel functionality and thus, need to be further 
investigated” (Kunz et al. 2009). 
 The effect of prebiotics on the human gastrointestinal microbiota has been 
the subject of extensive study.  This interest has been due largely to the 
bifidogenic properties of prebiotics and the many observations showing that high 
levels of bifidobacteria in the intestinal tract are correlated with health benefits in 
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humans.  Specifically, these organisms have been associated with increased 
resistance to infection and diarrhea (Saavedra 1994; Tojo et al. 1987; Yamazaki 
et al. 1985), stimulation of the immune system (Kirjavainen et al. 2002; Sekine et 
al. 1985), and protection against cancer (Reddy et al. 1993) as well as increased 
production of short chain fatty acids.  Convincing evidence has also emerged 
showing that bifidobacteria are the main species colonizing the infant 
gastrointestinal tract and that a bifidobacteria-rich microbiota protects the infant 
against pathogenic bacteria (Stark et al. 1982; Moro et al. 2002; Penders et al. 
2006; Weizman et al. 2005). However, the proportion of bifidobacteria decreases 
with age, thus efforts to restore or increase this population are warranted.   
Galactooligosaccharides (GOS) 
Commercial GOS is enzymatically synthesized from lactose using 
glycoside hydrolases (Roode et al. 2003) that catalyze transgalactosylation 
reactions (Crittenden et al. 1996).  Resulting products have different linkages 
depending on the enzyme source.  Commercially available GOS commonly 
includes β-1,3, β-1,4, or β-1,6 linkages (Torres et al. 2010).  Like other prebiotics, 
GOS selectively stimulates the growth of bifidobacteria and lactobacilli in the host 
gastrointestinal tract (Teuri et al. 1998; Moro et al. 2002; Bouhnik et al. 2004; 
Depeint et al. 2008). Doses necessary to elicit a bifidogenic response vary from 
2.5 to 10 g per day (Moro et al. 2002; Sako 1999; Depeint et al. 2008; Silk et al. 
2009).  However, recent studies also suggest that the bifidogenic effect of GOS 
is not only dose dependant, but relies on undefined host factors (Davis et al. 
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2010). GOS is marketed throughout the world and is self-affirmed as GRAS in 
the U.S. 
Inulin 
Inulin, a naturally-occurring plant polysaccharide, is one of the most widely 
consumed prebiotics.  It is a β-2,1 fructan with a degree of polymerization (DP) 
ranging from 2 to 60 (Costabile et al. 2010).  Inulin is characterized for having a 
bifidogenic effect when consumed in a regular basis. Human trials have been 
reported that show significant increases in bifidobacteria after regular 
consumption of inulin at doses ranging from 5 to 40 g/day (Kolida et al. 2007; 
Kruse et al. 1999; Gibson 1995; Kleessen et al. 1997; Kleessen et al. 2007; de 
Preter et al. 2008).  Inulin is legally classified as a food ingredient in all the 
countries in which it is used .  
Fructooligosaccharides (FOS)  
Two forms of fructooligosaccharides (FOS) are produced commercially.  
One form is derived from hydrolysis of inulin and consists mainly of β-2,1 fructose 
oligosaccharides, along with fructooligosaccharides chains containing glucose at 
the terminal end.  The other commercial form of FOS is obtained enzymatically 
from sucrose via a transfructosylation reaction.  This FOS contains a mixture of 
oligosaccharides, each consisting of glucose linked to two, three, or four fructose 
units (Molis et al. 1996). Human trials where FOS was consumed on a regular 
basis showed an increase in bifidobacterial levels; daily doses ranged from 2.5 to 
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20 g/day. (Bouhnik et al. 1999; Tuohy et al. 2001; Buddington et al. 1996; Menne 
et al. 2000; Bouhnik et al. 2007; Guigoz 2002; Williams et al. 1994) 
Xylooligosaccharides (XOS) 
Xylooligosaccharides are sugar oligomers made up of xylose units. They 
are found naturally in bamboo, fruits, vegetables, milk, and honey and are 
industrially produced form lignocellulosic materials (LCM) which come from a 
variety of feedstocks (Vázquez 2000).  There are three different approaches 
used to produce XOS from xylan-rich feedstocks: a) enzyme treatments of 
native, xylan containing LCM, b) chemical fractionation of LCM to isolate or 
solubilize xylan, with further enzymatic hydrolysis of the polymer to XOS, and c) 
hydrolytic degradation of xylan to XOS by steam, water or dilute solutions of 
mineral acids (Vázquez 2000). As for other prebiotics, XOS have been reported 
to modulate the gut microbiota, especially stimulating the growth of Bifidobacteria 
(Rycroft et al. 2001; Zampa et al. 2004).  Although data on human studies is 
limited, studies have shown increases of 10 to 30% in bifidobacteria following 
consumption of XOS.  
Polydextrose (PDX) 
Polydextrose (PDX) is a polysaccharide synthesized by random 
polymerization of glucose and sorbitol, using an appropriate acid catalyst at high 
temperature and partial vacuum conditions. It is widely used as a low calorie 
bulking agent in prepared foods (Jie et al. 2000).  Unlike other prebiotics, PDX is 
only partially fermented by intestinal microorganisms, due to the nature of the 
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glycosidic bonds, and high amounts are excreted in feces (Achour et al. 1994; 
Figdor et al. 1981).  The partial fermentation in the large intestine leads to 
reduced transit time, softer stools, and lower fecal pH (Achour et al. 1994).  The 
prebiotic activity of PDX remains unclear, although there are reports that it 
promotes proliferation of favorable microflora, including bifidobacteria, and 
decreases bowel pH (Jie et al. 2000). 
Mannan oligosaccharides (MOS) 
Mannan oligosaccharides (MOS) are derived via partial hydrolysis of the 
polysaccharide, mannan. The latter consist of α-1,4linked mannose monomers.  
They are obtained commercially either from plant material or from yeast cell 
walls.  MOS are widely used in cattle, swine, and poultry feed.(Dimitroglou et al. 
2009) They have been shown to improve gut function and health by increasing 
the integrity, uniformity and height of the villi, which results in a higher absorption 
efficiency in the gastrointestinal tract. (Iji et al. 2001; Hooge 2004; Castillo et al. 
2008; Spais et al. 2003; Sims et al. 2004) Supplementation of poultry diets with 
MOS has shown a positive response in body weight and feed conversion; 
especially with cage-housed commercial broiler chicks (Kumprecht et al. 1997). 
In addition, a study by Savage et al. 1996 showed that inclusion of MOS at 1 g/kg 
diet enhanced both IgG and IgA serum antibody levels in turkey poults. The 
benefits obtained from diet supplementation with MOS are attributed with several 
factors, including modification of the intestinal microflora of the animals (Shane et 
al. 2001).  
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Pectic oligosaccharides (POS) 
Pectins are complex polysaccharides that represent one of the major 
components of the plant cell wall of dicotyledonous plants (Willats 2000; 
Mandalari et al. 2006). They are considered soluble dietary fiber and exert 
physiological effects on the gastrointestinal tract consistent with other fibers, in 
that they delay gastrointestinal emptying (Flourie et al. 1985), reduce gut transit 
time (Spiller et al. 1980), and reduce glucose absorption rates (Jenkins et al. 
1977).  Pectic oligosaccharides (POS) are formed via enzymatic hydrolysis of 
pectins.  Pectin is a heteropolysaccharide and contains several sugars, but the 
primary monomers are α-1,4-linked galactosyluronic acid residues.   The 
enzymatically generated POS have been reported in several in vitro studies to 
have prebiotic activity (Manderson et al. 2005; E. Olano-Martin et al. 2002), 
based on increases in bifidobacteria. 
Chitooligosaccharides (COS) 
Chitin is a linear polysaccharide consisting of β-1, 4 linked N-acetyl-D-
glucosamine residues. It is considered as one of the most abundant 
polysaccharides in nature, after cellulose.  It is mainly found in the cell walls of 
fungi and yeasts and the exoskeleton of arthropods and insects (Aam et al. 2010; 
Minke et al. 1978).  Partial deacetylation of chitin yields chitosan, a 
heteropolymer of N-acetyl-D-glucosamine and D-glucosamine residues.  
Chitooligosaccharides (COS) are oligomers that can be obtained from chitosan 
either chemically or enzymatically via synthesis with glycosyl hydrolases (Aam et 
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al. 2010).  Although the prebiotic activity of COS remains unclear, reports have 
indicated that COS has antimicrobial activity mediated, in part, by adherence 
inhibition (Rhoades et al. 2006; Xia et al. 2011). 
The antiadherence model 
Attachment of pathogenic bacteria to host cell surfaces is the first and in 
many cases, one of the most important steps that occur during the infection 
process (Klemm et al. 2010; Bavington et al. 2005; Shoaf et al. 2006). Bacterial 
adhesion is mediated by several different physical and biological processes, as 
shown in Figure 1. In general, physical forces influence the proximity of the 
bacteria to the surface of the host cell only up to about 5 nm (Busscher 1987). A 
much stronger and mostly irreversible complex is then formed between specific 
bacterial adherence proteins and complementary host receptors (Pinzón-Arango 
et al. 2009; Abu-Lail et al. 2003). These specific interactions are mediated 
primarily by lectin-like molecules that recognize specific carbohydrates located at 
the surface of epithelial cells.  Lectins are defined as structurally diverse, 
carbohydrate-binding proteins.  Bacterial lectins are organized as thin-thread-like 
organelles called fimbriae or pili (Bavington et al. 2005; Klemm et al. 2010; 
Sharon 2006).  The structural differences between different lectins are based on 
a small globular carbohydrate-recognition domain; slight chemical differences in 
these domains allow for the selectivity of each adhesin to its target receptor 
(Shoaf-Sweeney et al. 2008; Weis et al. 1996). Thus, the specificity of a 
pathogen for a particular tissue or host is dependent on the type of 
oligosaccharide receptors coating the epithelial cell surface (Shoaf-Sweeney et 
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al. 2008). Bacterial attachment not only enables the organism to avoid 
displacement by the host’s natural cleansing mechanisms (e.g., peristalsis, bile 
acid excretion, flux, etc.), but also provides access of the organism to sources of 
nutrients located at the epithelial cell surface.  Ultimately, bacterial adherence 
promotes the organism’s potential for colonization and infection (Sinclair et al. 
2009). Bacteria that are incapable of expressing functional adhesins are not able 
to adhere and initiate infections, suggesting that adherence for these bacteria is 
an essential step in pathogenesis (Boddicker et al. 2002; Cleary 2004).  
Importantly, these observations imply that agents that block the initial attachment 
of potential pathogens to host cell surfaces could significantly reduce or prevent 
bacterial infections (Ziegler et al. 2007). 
 
Figure 1. Bacterial adhesion involving lectin-carbohydrate interactions: 
bacterial lectin-host glycoprotein (A1); bacterial lectin-host glycolipid (A2); 
host lectin-bacterial LPS (A3); hydrophobin-protein interactions (B); 
protein-protein interactions (C). Adapted from Ofek et al. 2003. 
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One group of substances that have been considered as anti-adherence 
agents includes prebiotic oligosaccharides.   Accordingly, they are proposed to 
act as molecular decoys that mimic the carbohydrate binding sites recognized by 
the pathogen. The model is based on the observation that certain prebiotic 
oligosaccharides have similar structures to the ones found in the surface of 
epithelial cells (Kunz et al. 2000; Shoaf et al. 2006). Once inside the GI tract, the 
pathogen will recognize the prebiotic as a binding site, adhere, and be removed 
from the system.  Oligosaccharides that have been shown to have anti-
adherence activity include oligosaccharides derived from human milk, as well as 
the commercial prebiotics, GOS, FOS, inulin, lactulose, and raffinose (Shoaf et 
al. 2006). Plant extracts and other molecules have also been tested and reported 
to have anti-adherence activity.  Several of these will be briefly reviewed in the 
next section. 
Anti-adherent oligosaccharides from human milk 
Human milk is not only a rich source of protein, fat, and other nutrients, 
but it also contains a large carbohydrate fraction (7%) consisting of lactose and a 
complex mixture of oligosaccharides (Zivkovic et al. 2010); between 5 and 23 
g/L. (Kunz et al. 2000; Coppa et al. 1993). Many of these human milk 
oligosaccharides (HMO) have similar structures to those carbohydrates found in 
the surface of intestinal epithelial cells (Sharon et al. 2000; 2002).  More than 130 
different HMO’s (Kunz et al. 2000), are known to be produced during the first 
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several months of lactation (Ben et al. 2004)  More recent analyses have 
identified as many as 200 molecular species in pooled human  milk samples 
(Zivkovic et al. 2010). The basic structure of HMOs is comprised of lactose at the 
reducing end, extended by N-acetyllactosamine units. The structural diversity is 
granted by fucose and sialic acid residues at the terminal positions (Zivkovic et 
al. 2010). The structures of the identified HMO’s consist of neutral and acidic 
oligosaccharides, terminated by fucose (50 – 70%) and sialic acid (5 -15%). 
(Ninonuevo et al. 2006)  When tested in vitro, HMO have been reported to have 
high affinity for bacterial adhesins (Newburg 2000; Miller et al. 1994; Newburg et 
al. 2004; Kobata 2003).  They have been reported to inhibit adhesion of 
Escherichia coli, Vibrio cholerae, and Salmonella fyris to a Caco-2 tissue culture 
cell line (Coppa et al. 2006). Other studies have reported that HMO inhibit 
adherence of Campylobacter jejuni (Ruiz-Palacios et al. 2003), Streptococcus 
pneumoniae and Haemophilus influenzae to human cell lines (Andersson et al. 
1986).  Despite their effectiveness as antiadhesives agents, they are obviously 
are not food grade and cannot be used as food ingredients. 
Galactooligosaccharides as anti-adherent agents 
Commercially available GOS has been tested for antiadherent activity 
against several enteric pathogens.  Studies have shown that GOS inhibits the 
adherence of Escherichia coli, Salmonella enterica serovar Typhimurium and two 
different strains of Cronobacter sakazakii to tissue culture cells at a concentration 
of 16mg/ml (Shoaf et al. 2006; Quintero et al. 2011; McGowan et al. 2011 
manuscript in preparation) and suggested that anti-adherent activity against E. 
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coli seems to be dose dependant until it reaches a plateau at a concentration of 
16 mg/ml. Searle et al. also reported adherence inhibition of S. typhimurium by 
GOS in a mouse model (Searle et al. 2009).  
Mannan oligosaccharides as anti-adherent agents 
 It is well known that the Type 1 fimbriae from Salmonella sp. and 
Escherichia coli are mannose-sensitive, in that free mannose is capable of 
inhibiting adherence of these bacteria, as well as other pathogens, to host 
tissues (Firon 1982; Neeser et al. 1986; Old 1972; Salit 1977; Kisiela et al. 2006) 
Ganan et al. 2009 reported that yeast derived mannoproteins inhibit  adherence 
of Campylobacter jejuni to a Caco-2 cell line. Their results indicated that the 
availability of mannose in the mannoprotein fraction seemed to be highly 
important for inhibiting adherence and invasion. Furthermore, protective effects 
with dietary mannose were also reported against Campylobacter jejuni 
colonization in chickens (Schoeni et al. 1994). Other studies have shown that 
adherence of Escherichia coli to epithelial cells can be inhibited or reversed by 
the addition of mannose and it derivatives.(Ofek et al. 1978) Moreover, α-D-
mannopyranoside has been shown to prevent urinary tract infection in mice by 
inhibiting adherence and further colonization of the urinary tract by E. coli 
(Aronson et al. 1979). Another study showed that chicks challenged with 
Salmonella typhimurium had decreased cecal colonization when mannan 
oligosaccharides were added to their diet (Spring et al. 2000). 
Pectic oligosaccharides as anti-adherent agents 
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Pectic oligosaccharides have been reported to inhibit invasion of 
Campylobacter jejuni to Caco-2 cells in a dose dependent manner. (Ganan et al. 
2010).  Olano-Martin et al. 2003 assessed the ability of pectic oligosaccharides to 
neutralize Escherichia coli Shiga toxins at various doses. A concentration of 10 
mg/ml was reported to completely inhibit Shiga toxin 1 and Shiga toxin 2.   
Despite these results, however, further research is needed to determine 
antiadherence properties against other pathogens.  
Other anti-adherent agents 
In addition to oligosaccharides, some plant extracts and glycoproteins 
have been reported to have antiadherence activity. Some of the mechanisms by 
which they inhibit bacterial adherence have been well studied, while others need 
further research. Of particular interest is the large molecular weight fraction from 
cranberry concentrate and lactoferrin, a glycoprotein found in high concentrations 
in milk.  
Anti-adherent properties of cranberry 
Cranberry juice has been consumed for decades for the purpose of 
treating and preventing urinary tract infections. Urinary tract infections (UTI) are 
one of the most prevalent diseases among females; approximately eight million 
people per year experience UTIs in the U.S. (Cohn et al. 2004).  They are most 
often caused by Gram-negative bacteria, primarily uropathogenic Escherichia coli 
(UPEC) (Johnson 2003).  Although UTIs can usually be treated successfully with 
antibiotics, when infections become recurrent, there is a growing concern about 
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antibiotic resistance (Liu et al. 2006; Wilson et al. 2004). Recently, oral 
consumption of cranberry products was reported to reduce UTI’s (Raz et al. 
2004). The ability of cranberry to reduce or prevent infections caused by UPEC 
has been attributed to the presence of two different compounds in cranberry 
products; a high molecular weight component and proanthocyanidins (PACs).  
Both were reported to inhibit adhesion of UPEC to uroepithelial cells (Rahbar et 
al. 2010).  Zafriri et al. 1989 reported that the non-dialyzable material of a 
cranberry cocktail inhibited the activity of a mannose-specific Type 1 fimbriated 
E. coli. This was assayed by yeast aggregometry, hemagglutination, adherence 
to tissue culture cells, and attachment to mouse peritoneal macrophages.  The 
mechanism by which cranberry inhibits adhesion is poorly understood, although it 
has been reported that some components interact directly with P-fimbriae by 
altering their conformation and by binding of hydrophilic components, hence 
inhibiting adherence (Liu et al. 2006). Interestingly, Sobota 1984 reported that 
urine from mice and human still contained components that reduced E. coli 
adherence after the consumption of cranberry products, suggesting that the 
active compounds might not be destroyed during digestion.  Other studies, both 
in vitro and in vivo, have shown that cranberry juice constituents inhibit adhesion 
of Helicobacter pylori (Burger et al. 2000; Burger et al. 2002; Shmuely et al. 
2004). Furthermore, the high molecular weight component in cranberry juice has 
been shown to reduce salivary Streptococcus mutans in a randomized controlled 
population (Weiss et al. 2004).  The effect was attributed to the ability of the 
17 
 
HMW component to inhibit adhesion and biofilm formation of Streptococcus onto 
tooth surfaces. (Steinberg et al. 2005; 2004; Weiss et al. 2004) 
Anti-adherent properties of lactoferrin 
Lactoferrin is an iron-binding protein that is found in high concentrations in 
human milk and in lower concentrations in other fluids (Legrand et al. 2005). It 
can be found in human colostrum in concentrations up to 7g/l, (Masson et al. 
1971) and up to 1 mg/ml in human milk after the first month of lactation. In bovine 
colostrum, it can reach up to 1.5 mg/ml. (Theresa J Ochoa et al. 2009).  It is a 
very stable protein and is highly resistant to proteolytic degradation (Lönnerdal 
2009). Lactoferrin can be recovered in the stool of breast fed infants, indicating it 
is at least partially resistant to digestion in the gut (Davidson et al. 1987). 
 Several biological functions have been attributed to lactoferrin, including 
antimicrobial, anti-inflammatory, and immunomodulatory activities (Brock 2002; 
Kruzel et al. 2002; Ward et al. 2002; Legrand et al. 2008; Actor et al. 2009).  One 
of the first mechanisms that account for the antimicrobial properties for lactoferrin 
was based on its ability to sequester iron, thus depriving pathogens from this 
essential nutrient (Bullen et al. 1972; Arnold et al. 1980; Nicola Orsi 2004).  
Although lactoferrin is effective against several pathogens, this activity is 
markedly reduced upon iron supplementation (Arnold et al. 1980; Kalmar et al. 
1988; Yamauchi et al. 1993; Valenti et al. 2005).  There are also iron-
independent mechanisms by which lactoferrin inhibits pathogens, specifically via 
the direct interaction of lactoferrin with bacterial cell surfaces (Dalmastri et al. 
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1988; Carol A. Bortner, Roland R. Arnold 1989).  Lactoferrin binds the lipid A 
component of the lipopolysaccharide (LPS) in Gram-negative bacteria, affecting 
membrane permeability, (Appelmelk et al. 1994; Brandenburg et al. 2001; 
Shahriar et al. 2006) and thus releasing LPS from the membrane (Appelmelk et 
al. 1994; Brandenburg et al. 2001; Ellison et al. 1988). 
 Several other iron-independent activities of lactoferrin exist that exert an 
antimicrobial effect.  It has been demonstrated that lactoferrin has a serine 
protease-like activity and it is able to proteolytically degrade two colonization 
factors expressed by Haemophilus influenzae, attenuating its virulence and 
preventing colonization (Qiu 1998; Jenssen et al. 2009).  Lactoferrin may also 
interfere with the Type III secretory system that is used by many pathogenic 
bacteria to adhere and infect host cells (Ochoa et al. 2003; DeVinney et al. 1999; 
Goosney et al. 1999).   Studies have shown that lactoferrin is able to degrade 
virulence proteins secreted by Shigella flexeneri, resulting in inhibition of bacterial 
uptake into host cells (Gomez et al. 2001; Gomez et al. 2003). A similar result 
was observed with enteropathogenic Escherichia coli, where lactoferrin caused 
loss and degradation of several Type III secretion proteins, resulting in reduced 
bacterial virulence and adherence to host cells (Ochoa et al. 2003).  Additionally, 
enterotoxigenic Escherichia coli (ETEC) strains were reported to bind a 
significant amount of lactoferrin (Naidu et al. 1991; Giugliano et al. 1995), which 
may have accounted for the adherence inhibition observed for ETEC on HEp-2 
tissue culture cells (Giugliano et al. 1995). Similarily, Bessler et al. 2006 reported 
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that the direct interaction of lactoferrin with the bacterial surface inhibits 
adherence and invasion of Salmonella typhimurium. 
Prebiotics as therapeutic agents against the emerging pathogen 
Cronobacter sakazakii  
 Infections caused by foodborne pathogens continue to be a major concern 
to the food industry, consumers, and public health authorities.  Often these 
infections are self-limiting, but even for more serious cases, few therapies are 
available.  In general, even antibiotics are often of limited value.  Research 
efforts aimed at identifying new therapeutic or prophylactic strategies are 
attracting considerable attention.  Targets for such approaches include not only 
pathogens, such as Escherichia coli and Salmonella spp., that have long been 
associated with foodborne disease, but also recently recognized pathogens, such 
as Cronobacter spp. 
 The genus Cronobacter is located within the family of the 
Enterobacteriaceae.  They are motile, non-sporeforming, rod shaped, Gram 
negative facultative anaerobes (Chenu et al. 2009). It now appears that all 
Cronobacter species are opportunistic pathogens (Johler et al. 2010; Hartmann 
et al. 2010).  Some species, in particular, Cronobacter sakazakii, are responsible 
for causing rare, but severe forms of meningitis, sepsis and necrotizing 
enterocolitis (NEC) in newborn infants and neonates (Acker et al. 2001; Hunter et 
al. 2008; Muytjens et al. 1983; Biering et al. 1989; Bar-Oz et al. 2007). The infant 
mortality rate due to infection of this organism has been reported to be 40 – 80%, 
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and up to 20% of neonates that survive develop serious neurological 
complications (Iversen et al. 2003). Although there is little information about the 
natural reservoir of this organism, it has been isolated from food processing 
plants and food products, including cheese products, cured meats, vegetables, 
and herbs and spices. However, it is the association of C. sakazakii with 
powdered infant formula (PIF) that has attracted the most concern.  Indeed, PIF 
has been implicated in several outbreaks (Forsythe 2005) and sporadic cases of 
C. sakazakii infections (Iversen et al. 2003). Powdered infant formula is now 
recognized as one of the main food sources for this organism (Iversen et al. 
2004; Weir 2002; Drudy et al. 2006; Mullane et al. 2006; Iversen 2004; Iversen et 
al. 2003).  In addition, the organism has been isolated from powdered milk 
processing plants as well as hospital utensils (spoons and blenders) used to 
prepare infant formula (Forsythe 2005).   
 Several factors contribute to the ability of C. sakazakii to persist in dry milk 
and PIF products.  The organism has a remarkable resistance to osmotic stress 
and desiccation, compared with other members of the Enterobacteriaceae, and 
can persist under desiccated conditions in infant formula for over two years 
(Breeuwer et al. 2003; Caubilla-Barron et al. 2007).  Additionally, it produces a 
yellow pigment that may protect the cells against UV rays and also has the ability 
to form capsules and fimbriae that enable the organism to adhere to different 
surfaces (Mullane et al. 2006).  These physiological characteristics not only 
enhance survival in the food production environment, but may also contribute to 
persistence in other environmental sources such as water, soil, and vegetables. 
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 Although the incidence of Cronobacter infections is unknown, CDC has 
estimated infection rates as low as 3 cases per year, worldwide.  However, 
because Cronobacter infections are most likely to involve newborn infants and 
neonates,with mortalities rates as high as 40%, the organism is still considered a 
serious public health threat.  The infectious dose has not been established 
although the Food and Agriculture Organization / World Health Organization 
(2004) has determined a tentatively oral infectious dose that ranges from 103 
CFU to 108 CFU.  
 The means by which C. sakazakii causes disease has only recently been 
investigated.  The organism appears to be able to trespass the intestinal barrier 
and establish a systemic infection (Kim et al. 2008). Kothary et al. 2007 
determined that Cronobacter synthesizes a zinc-containing metalloprotease that 
has collagenolytic activity that allows the organism to cross the blood-brain 
barrier. Hunter et al. 2008 suggested an association of Cronobacter with human 
NEC, an inflammatory intestinal disorder that affects 2%-5% of neonates and that 
has very high mortality rates.  In mammalian tissue culture, the organism has 
been shown to adhere to host cells and survive internally in macrophages 
(Pagotto et al. 2003).  However, the specific bacterial virulence factors implicated 
in the process are still unknown (Mittal et al. 2009).  An outer membrane protein 
A (OmpA) of C. sakazakii is also thought to play an important role in the 
attachment and invasion of Caco-2 cells (Kim et al. 2008). In general, invasion 
was directly correlated with cell contact time and MOI, suggesting that entry of 
the bacterium to Caco-2 cells may be receptor mediated and that C. sakazakii 
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invasion is an active process that requires bacterial de novo protein synthesis. 
The latter might be an important feature in systemic infection of neonates and 
infants due to their lack of a fully established gut epithelial lining and the normal 
microbiota (Kim et al. 2008). In contrast, another study demonstrated that C. 
sakazakii binds to rat intestinal epithelial cells without significant invasion (Hunter 
et al. 2008). 
Conclusion 
Prebiotic oligosaccharides are now commonly being used as food ingredients in 
many food products.  Several commercial prebiotics have been shown to 
mediate changes in the intestinal microbiota of the host, in particular, a 
bifidogenic effect when consumed on a regular basis.  Some prebiotics may also 
be able to directly inhibit infections caused by pathogenic bacteria via an anti-
adherence mechanism.  This latter activity has led investigators to consider 
adding anti-adherence prebiotics to powdered infant formula as a way to 
prophylactically reduce or prevent infections caused by C. sakazakii.  In addition, 
the ability of other novel prebiotics and natural plant or milk-derived materials 
may also have anti-adherent effects against pathogenic bacteria.  However, 
further research will be necessary to determine the feasibility of this approach. 
 The objectives of the research described in this thesis were to: (1) 
determine the ability of GOS alone and in combination with other selected 
commercial prebiotics to inhibit adherence of C. sakazakii to tissue culture cells; 
(2) to determine the ability of plant extracts such as a cranberry extract and 
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different oligosaccharides to inhibit adherence of enteropathogenic and 
enterohemorragic Escherichia coli, and Salmonella enterica serovar 
Typhimurium to tissue culture cells; (3) finally, to test the ability of lactoferrin to 
inhibit adherence of C. sakazakii, alone and in combination with two 
commercially available prebiotics, to tissue culture cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
References 
Aam, B. B., Heggset, E. B., Norberg, A. L., Sørlie, M., Vårum, K. M., and Eijsink, 
V. G. H. (2010). Production of chitooligosaccharides and their potential 
applications in medicine. Marine drugs 8, 1482-517.. 
Abu-Lail, N. I., and Camesano, T. A. (2003). Role of ionic strength on the 
relationship of biopolymer conformation, DLVO contributions, and steric 
interactions to bioadhesion of Pseudomonas putida KT2442. 
Biomacromolecules 4, 1000-12.. 
Achour, L, Flourie, B, Briet, F., Pellier, P., Marteau, P, and Rambaud, J. (1994). 
Gastrointestinal effects and energy value of polydextrose in healthy 
nonobese men. Am J Clin Nutr 59, 1362-1368. 
Acker, J. van, Smet, F. de, Muyldermans, G., Bougatef, A., Naessens, A., and 
Lauwers, S. (2001). Outbreak of necrotizing enterocolitis associated with 
Enterobacter sakazakii in powdered milk formula. Journal of clinical 
microbiology 39, 293-7.  
Actor, J. K., Hwang, S.-A., and Kruzel, M. L. (2009). Lactoferrin as a natural 
immune modulator. Current pharmaceutical design 15, 1956-73.  
Andersson, B., Porras, O., Hanson, L. A., Lagergard, T., and Svanborg-Eden, C. 
(1986). Inhibition of Attachment of Streptococcus pneumoniae and 
25 
 
Haemophilus influenzae by Human Milk and Receptor Oligosaccharides. 
Journal of Infectious Diseases 153, 232-237.  
Appelmelk, B. J., An, Y. Q., Geerts, M., Thijs, B. G., Boer, H. A. de, MacLaren, D. 
M., Graaff, J. de, and Nuijens, J. H. (1994). Lactoferrin is a lipid A-binding 
protein. Infect. Immun. 62, 2628-2632.  
Arnold, R. R., Brewer, M., and Gauthier, J. J. (1980). Bactericidal activity of 
human lactoferrin: sensitivity of a variety of microorganisms. Infect. Immun. 
28, 893-898.  
Aronson, M., Medalia, O., Schori, L., Mirelman, D., Sharon, N., and Ofek, I. 
(1979). Prevention of Colonization of the Urinary Tract of Mice with 
Escherichia coli by Blocking of Bacterial Adherence with Methyl  -D-
Mannopyranoside. Journal of Infectious Diseases 139, 329-332.  
Bar-Oz, B., Preminger, A., Peleg, O., Block, C., and Arad, I. (2007). Enterobacter 
sakazakii infection in the newborn. Acta Paediatrica 90, 356-358.  
Bavington, C., and Page, C. (2005). Stopping bacterial adhesion: a novel 
approach to treating infections. Respiration; international review of thoracic 
diseases 72, 335-44. 
Ben, X.M., Zhou, X.Y., Zhao, W.H., Yu, W.L., Pan, W., Zhang, W.L., Wu, S.M., 
Chirstien, M. V. B., and Anne, S. (2004). Supplementation of milk formula 
26 
 
with galacto-oligosaccharides improves intestinal micro-flora and 
fermentation in term infants. Chinese medical journal 117, 927-931.  
Bessler, H. C., Oliveira, I. R. de, and Giugliano, Loreny Gimenes (2006). Human 
milk glycoproteins inhibit the adherence of Salmonella typhimurium to HeLa 
cells. Microbiology and immunology 50, 877-82.  
Biering, G., Karlsson, S., Clark, N. C., Jonsdottir, K. E., Ludvigsson, P., and 
Steingrimsson, O. (1989). Three cases of neonatal meningitis caused by 
Enterobacter sakazakii in powdered milk. J. Clin. Microbiol. 27, 2054-2056.  
Boddicker, J. D., Ledeboer, N. A., Jagnow, J., Jones, B. D., and Clegg, S. 
(2002). Differential binding to and biofilm formation on, HEp-2 cells by 
Salmonella enterica Serovar Typhimurium is dependent upon allelic variation 
in the fimH gene of the fim gene cluster. Molecular Microbiology 45, 1255-
1265. 
Bode, L. (2006). Recent Advances on Structure, Metabolism, and Function of 
Human Milk Oligosaccharides. J. Nutr. 136, 2127-2130.  
Boehm, N., Stahl, Bernd, Miniello, V., and Moro, G. E. (2005). Prebiotic 
carbohydrates in human milk and formulas. Journal of Pediatrics, The 94, 
18-21. 
Bouhnik, Y., Achour, Lotfi, Paineau, D., Riottot, M., Attar, A., and Bornet, Francis 
(2007). Four-week short chain fructo-oligosaccharides ingestion leads to 
27 
 
increasing fecal bifidobacteria and cholesterol excretion in healthy elderly 
volunteers. Nutrition journal 6, 42.  
Bouhnik, Y., Raskine, L., Simoneau, G., Vicaut, E., Neut, C., Flourie, Bernard, 
Brouns, F., and Bornet, F. R. (2004). The capacity of nondigestible 
carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-
blind, randomized, placebo-controlled, parallel-group, dose-response 
relation study. Am J Clin Nutr 80, 1658-1664.  
Bouhnik, Y. et al. (1999). Short-Chain Fructo-Oligosaccharide Administration 
Dose-Dependently Increases Fecal Bifidobacteria in Healthy Humans. J. 
Nutr. 129, 113-116. 
Brandenburg, K., Jürgens, G., Müller, M., Fukuoka, S., and Koch, M. H. (2001). 
Biophysical characterization of lipopolysaccharide and lipid A inactivation by 
lactoferrin. Biological chemistry 382, 1215-25. 
Breeuwer, P., Lardeau, A., Peterz, M., and Joosten, H. M. (2003). Desiccation 
and heat tolerance of Enterobacter sakazakii. Journal of Applied 
Microbiology 95, 967-973. 
Brock, J. H. (2002). The Physiology of Lactoferrin. Biochem. Cell Biol 80, 1 - 6. 
Buddington, R., Williams, C., Chen, S., and Witherly, S. (1996). Dietary 
supplement of neosugar alters the fecal flora and decreases activities of 
some reductive enzymes in human subjects. Am J Clin Nutr 63, 709-716.  
28 
 
Bullen, J. J., Rogers, H. J., and Leigh, L. (1972). Iron-binding Proteins in Milk and 
Resistance to Escherichia coli Infection in Infants. BMJ 1, 69-75.  
Burger, O., Ofek, Itzhak, Tabak, Mina, Weiss, E. I., Sharon, Nathan, and 
Neeman, Ishak (2000). A high molecular mass constituent of cranberry juice 
inhibits Helicobacter pylori adhesion to human gastric mucus. FEMS 
Immunology & Medical Microbiology 29, 295-301.  
Burger, O., Weiss, Ervin, Sharon, Nathan, Tabak, Mina, Neeman, Ishak, and 
Ofek, Itzhak (2002). Inhibition of Helicobacter pylori adhesion to human 
gastric mucus by a high-molecular-weight constituent of cranberry juice. 
Critical reviews in food science and nutrition 42, 279-84. 
Busscher, H. (1987). Specific and non-specific interactions in bacterial adhesion 
to solid substrata. FEMS Microbiology Letters 46, 165-173.  
Carol A. Bortner, Roland R. Arnold, and R. D. M. (1989). Bactericidal effect of 
lactoferrin on Legionella pneumophila: effect of the physiological state of the 
organism. Canadian journal of microbiology 35, 1048-1051. 
Castillo, M., Martín-Orúe, S. M., Taylor-Pickard, J. A., Pérez, J. F., and Gasa, J. 
(2008). Use of mannanoligosaccharides and zinc chelate as growth 
promoters and diarrhea preventative in weaning pigs: Effects on microbiota 
and gut function. Journal of animal science 86, 94-101. 
29 
 
Caubilla-Barron, J., Hurrell, E., Townsend, S., Cheetham, P., Loc-Carrillo, C., 
Fayet, O., Prère, M.-F., and Forsythe, S J (2007). Genotypic and phenotypic 
analysis of Enterobacter sakazakii strains from an outbreak resulting in 
fatalities in a neonatal intensive care unit in France. Journal of clinical 
microbiology 45, 3979-85. 
Chenu, J. W., and Cox, J. M. (2009). Cronobacter ( ʼEnterobacter sakazakii'): 
current status and future prospects. Letters in applied microbiology 49, 153-
9.  
Cleary, J. (2004). Enteropathogenic Escherichia coli (EPEC) adhesion to 
intestinal epithelial cells: role of bundle-forming pili (BFP), EspA filaments 
and intimin. Microbiology 150, 527-538.  
Cohn, Evan B., Schaeffer, A. J. (2004). Urinary Tract Infections in Adults. The 
Scientific World JOURNAL 4, 76-88. 
Coppa, G. V., Gabrielli, O., Versalovic, J., and Wilson, M. (2008). Human milk 
oligosaccharides as prebiotics. 131-146.  
Coppa, Giovanni V, Zampini, L., Galeazzi, T., Facinelli, B., Ferrante, L., Capretti, 
R., and Orazio, G. (2006). Human milk oligosaccharides inhibit the adhesion 
to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and 
Salmonella fyris. Pediatric research 59, 377-82.  
30 
 
Coppa, Giovanni V., Gabrielli, Orazio, Pierani, P., Catassi, C., Carlucci, A., and 
Giorgi, P. L. (1993). Changes in Carbohydrate Composition in Human Milk 
Over 4 Months of Lactation. Pediatrics 91, 637-641.  
Costabile, A., Kolida, Sofia, Klinder, A., Gietl, E., Bäuerlein, M., Frohberg, C., 
Landschütze, V., and Gibson, Glenn R. (2010). A double-blind, placebo-
controlled, cross-over study to establish the bifidogenic effect of a very-long-
chain inulin extracted from globe artichoke ( Cynara scolymus) in healthy 
human subjects. British Journal of Nutrition 104, 1007-1017.  
Crittenden, R. (1996). Production, properties and applications of food-grade 
oligosaccharides. Trends in Food Science & Technology 7, 353-361. 
Available at: http://dx.doi.org/10.1016/S0924-2244(96)10038-8  
Dalmastri, C., Valenti, P., Visca, P., Vittorioso, P., and Orsi, N (1988). Enhanced 
antimicrobial activity of lactoferrin by binding to the bacterial surface. 
Microbiologica 11, 225-30.  
Davidson, L. A., and Lonnerdal, B. (1987). Persistence of Human Milk Proteins in 
the Breast-Fed Infant. Acta Paediatrica 76, 733-740. 
Davis, L. M. G., Martínez, I., Walter, J., and Hutkins, R (2010). A dose dependent 
impact of prebiotic galactooligosaccharides on the intestinal microbiota of 
healthy adults. International journal of food microbiology 144, 285-92.  
31 
 
Depeint, F., Tzortzis, George, Vulevic, Jelena, IʼAnson, K., and Gibson, Glenn R 
(2008). Prebiotic evaluation of a novel galactooligosaccharide mixture 
produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, 
in healthy humans: a randomized, double-blind, crossover, placebo-
controlled intervention study. Am J Clin Nutr 87, 785-791.  
DeVinney, R., Gauthier, A., Abe, A., and Finlay, B. B. (1999). Enteropathogenic 
Escherichia coli: a pathogen that inserts its own receptor into host cells. 
Cellular and molecular life sciences : CMLS 55, 961-76.  
Dimitroglou, A., Merrifield, D. L., Moate, R., Davies, S. J., Spring, P., Sweetman, 
J., and Bradley, G. (2009). Dietary mannan oligosaccharide supplementation 
modulates intestinal microbial ecology and improves gut morphology of 
rainbow trout, Oncorhynchus mykiss (Walbaum). Journal of animal science 
87, 3226-34. 
Drudy, D., Mullane, N. R., Quinn, T., Wall, P. G., and Fanning, S. (2006). 
Enterobacter sakazakii: an emerging pathogen in powdered infant formula. 
Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 42, 996-1002.  
Ellison, R. T., Giehl, T. J., and LaForce, F. M. (1988). Damage of the outer 
membrane of enteric gram-negative bacteria by lactoferrin and transferrin. 
Infect. Immun. 56, 2774-2781.  
32 
 
Figdor, S. K., and Rennhard, H. H. (1981). Caloric utilization and disposition of 
[14C]polydextrose in the rat. Journal of Agricultural and Food Chemistry 29, 
1181-1189.  
FIRON, N. (1982). Interaction of mannose-containing oligosaccharides with the 
fimbrial lectin of Escherichia coli. Biochemical and Biophysical Research 
Communications 105, 1426-1432.  
Flourie, B, Vidon, N., Chayvialle, J., Palma, R., Franchisseur, C., and Bernier, J. 
(1985). Effect of increased amounts of pectin on a solid-liquid meal digestion 
in healthy man. Am J Clin Nutr 42, 495-503.  
Forsythe, Stephen J (2005). Enterobacter sakazakii and other bacteria in 
powdered infant milk formula. Maternal & child nutrition 1, 44-50. 
Ganan, M., Collins, M., Rastall, R., Hotchkiss, A. T., Chau, H. K., Carrascosa, A. 
V., and Martinez-Rodriguez, A. J. (2010). Inhibition by pectic 
oligosaccharides of the invasion of undifferentiated and differentiated Caco-2 
cells by Campylobacter jejuni. International journal of food microbiology 137, 
181-5.  
Ganan, M. , Carrascosa, A. V. , Pascual-Teresa, S. de, and Martinez-Rodriguez, 
A. J. (2009). Inhibition by Yeast-Derived Mannoproteins of Adherence to and 
Invasion of Caco-2 Cells by Campylobacter jejuni. Journal of Food 
Protection® 72, 5.  
33 
 
Gibson, G. (1995). Selective stimulation of bifidobacteria in the human colon by 
oligofructose and inulin. Gastroenterology 108, 975-982.  
Gibson, G R, and Roberfroid, M B (1995). Dietary modulation of the human 
colonic microbiota: introducing the concept of prebiotics. The Journal of 
nutrition 125, 1401-12.  
Gibson, G. R., McCartney, A. L., and Rastall, R. A. (2005). Prebiotics and 
resistance to gastrointestinal infections. British Journal of Nutrition 93, S31-
S34.  
Gibson, Glenn R., Probert, H. M., Loo, J. V., Rastall, Robert A., and Roberfroid, 
Marcel B. (2004). Dietary modulation of the human colonic microbiota: 
updating the concept of prebiotics. Nutrition Research Reviews 17, 259-275.  
Giugliano, L. G., Ribeiro, S. T. G., Vainstein, M. H., and Ulhoa, C. J. (1995). Free 
secretory component and lactoferrin of human milk inhibit the adhesion of 
enterotoxigenic Escherichia coli. Journal of Medical Microbiology 42, 3-9.  
Gomez, H F, Herrera-Insua, I., Siddiqui, M. M., Diaz-Gonzalez, V. A., Caceres, 
E., Newburg, D S, and Cleary, T G (2001). Protective role of human 
lactoferrin against invasion of Shigella flexneri M90T. Advances in 
experimental medicine and biology 501, 457-67.  
34 
 
Gomez, Henry F., Ochoa, Theresa J., Carlin, L. G., and Cleary, Thomas G. 
(2003). Human Lactoferrin Impairs Virulence of Shigella flexneri. The Journal 
of Infectious Diseases 187, 87 - 95.  
Goosney, D. L., Knoechel, D. G., and Finlay, B. B. (1999). Enteropathogenic E. 
coli, Salmonella, and Shigella: masters of host cell cytoskeletal exploitation. 
Emerging infectious diseases 5, 216-23.  
Grizard, D. Barthomeuf, C. (1999). Enzymatic synthesis and structure 
determination of NEO-FOS. Food Biotechnology.  
Guigoz, Y. (2002). Effects of oligosaccharide on the faecal flora and non-specific 
immune system in elderly people. Nutrition Research 22, 13-25.  
Hartmann, I., Carranza, P., Lehner, A., Stephan, R., Eberl, L., and Riedel, K. 
(2010). Genes involved in Cronobacter sakazakii biofilm formation. Applied 
and environmental microbiology 76, 2251-61.  
Hooge, D. M. (2004). Meta-analysis of broiler chicken pen trials evaluating 
dietary mannan oligosaccharide, 1993-2003. Int. J. Poult. Sci 3, 163–174.  
Hunter, C. J., Singamsetty, V. K., Chokshi, N. K., Boyle, P., Camerini, V., Grishin, 
A. V., Upperman, J. S., Ford, H. R., and Prasadarao, N. V. (2008). 
Enterobacter sakazakii enhances epithelial cell injury by inducing apoptosis 
in a rat model of necrotizing enterocolitis. The Journal of infectious diseases 
198, 586-93.  
35 
 
Iji, P. A., Saki, A. A., and Tivey, D. R. (2001). Intestinal structure and function of 
broiler chickens on diets supplemented with a mannan oligosaccharide. 
Journal of the Science of Food and Agriculture 81, 1186-1192.  
Iversen, C. (2004). Isolation of Enterobacter sakazakii and other 
Enterobacteriaceae from powdered infant formula milk and related products. 
Food Microbiology 21, 771-777.  
Iversen, C., and Forsythe, S. (2003). Risk profile of Enterobacter sakazakii, an 
emergent pathogen associated with infant milk formula. Trends in Food 
Science & Technology 14, 443-454.  
Iversen, C., Lane, M., and Forsythe, S J (2004). The growth profile, 
thermotolerance and biofilm formation of Enterobacter sakazakii grown in 
infant formula milk. Letters in applied microbiology 38, 378-82.  
Jenkins, D. J., Gassull, M. A., Leeds, A. R., Metz, G., Dilawari, J. B., Slavin, B., 
and Blendis, L. M. (1977). Effect of dietary fiber on complications of gastric 
surgery: prevention of postprandial hypoglycemia by pectin. 
Gastroenterology 73, 215-7. 
Jenness, R. (1979). The composition of human milk. Seminars in perinatology 3, 
225-39.  
Jenssen, H., and Hancock, R. E. W. (2009). Antimicrobial properties of 
lactoferrin. Biochimie 91, 19-29.  
36 
 
Jie, Z., Bang-yao, L., Ming-jie, X., Hai-wei, L., Zu-kang, Z., Ting-song, W., and 
Craig, S. A. (2000). Studies on the effects of polydextrose intake on 
physiologic functions in Chinese people. Am J Clin Nutr 72, 1503-1509.  
Johler, S., Stephan, R., Hartmann, I., Kuehner, K. A., and Lehner, A. (2010). 
Genes involved in yellow pigmentation of Cronobacter sakazakii ES5 and 
influence of pigmentation on persistence and growth under environmental 
stress. Applied and environmental microbiology 76, 1053-61.  
Johnson, J. R. (2003). Microbial virulence determinants and the pathogenesis of 
urinary tract infection. Infectious disease clinics of North America 17, 261-78, 
viii.  
Kalmar, J. R., and Arnold, R. R. (1988). Killing of Actinobacillus 
actinomycetemcomitans by human lactoferrin. Infect. Immun. 56, 2552-2557.  
Kim, K.-P., and Loessner, M. J. (2008). Enterobacter sakazakii invasion in 
human intestinal Caco-2 cells requires the host cell cytoskeleton and is 
enhanced by disruption of tight junction. Infection and immunity 76, 562-70.  
Kirjavainen, P. V., Arvola, T., Salminen, S. J., and Isolauri, E. (2002). Aberrant 
composition of gut microbiota of allergic infants: a target of bifidobacterial 
therapy at weaning? Gut 51, 51-55.  
Kisiela, D., Laskowska, A., Sapeta, A., Kuczkowski, M., Wieliczko, A., and 
Ugorski, M. (2006). Functional characterization of the FimH adhesin from 
37 
 
Salmonella enterica serovar Enteritidis. Microbiology (Reading, England) 
152, 1337-46.  
Kleessen, B, Sykura, B., Zunft, H., and Blaut, M (1997). Effects of inulin and 
lactose on fecal microflora, microbial activity, and bowel habit in elderly 
constipated persons. Am J Clin Nutr 65, 1397-1402.  
Kleessen, Brigitta, Schwarz, S., Boehm, A., Fuhrmann, H., Richter, A., Henle, T., 
and Krueger, M. (2007). Jerusalem artichoke and chicory inulin in bakery 
products affect faecal microbiota of healthy volunteers. British Journal of 
Nutrition 98, 540-549. 
Klemm, P., Vejborg, R. M., and Hancock, V. (2010). Prevention of bacterial 
adhesion. Applied microbiology and biotechnology 88, 451-459-459.  
Kobata, A. (2003). Possible application of milk oligosaccharides for drug 
development. Chang Gung medical journal 26, 621-36.  
Kolida, Sofia, and Gibson, Glenn R. (2007). Prebiotic Capacity of Inulin-Type 
Fructans. J. Nutr. 137, 2503S-2506.  
Kothary, M. H., McCardell, B. A., Frazar, C. D., Deer, D., and Tall, B. D. (2007). 
Characterization of the zinc-containing metalloprotease encoded by zpx and 
development of a species-specific detection method for Enterobacter 
sakazakii. Applied and environmental microbiology 73, 4142-51.  
38 
 
Kruse, H.-P., Kleessen, Brigitta, and Blaut, Michael (1999). Effects of inulin on 
faecal bifidobacteria in human subjects. British Journal of Nutrition 82, 375-
382.  
Kruzel, M. L., Harari, Y., Mailman, D., and Actor, J. K. (2002). Differential effects 
of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-
induced inflammatory responses in mice. Clinical and Experimental 
Immunology 130, 25-31.  
Kumprecht, I., Zobac, P., Siske, V., Sefton, A., and Spring, P. (1997). Effects of 
dietary mannanoligosaccharide level on performance and nutrient utilization 
of broilers. Poultry Sci 76, 132. 
Kunz, C., Kuntz, S., and Rudloff, S. (2009). Chapter 6 INTESTINAL FLORA. 
Media, 67-79. 
Kunz, C., Rudloff, S., Baier, W., Klein, N., and Strobel, S. (2000). 
Oligosaccharides in human milk: structural, functional, and metabolic 
aspects. Annual review of nutrition 20, 699-722.  
Legrand, D, Elass, E, Carpentier, M, and Mazurier, J (2005). Lactoferrin: a 
modulator of immune and inflammatory responses. Cellular and molecular 
life sciences : CMLS 62, 2549-59.  
39 
 
Legrand, Dominique, Pierce, A., Elass, Elisabeth, Carpentier, Mathieu, Mariller, 
C., and Mazurier, Joël (2008). Lactoferrin structure and functions. Advances 
in experimental medicine and biology 606, 163-94. 
Liu, Y., Black, M. A., Caron, L., and Camesano, T. A. (2006). Role of cranberry 
juice on molecular-scale surface characteristics and adhesion behavior of 
Escherichia coli. Biotechnology and bioengineering 93, 297-305.  
Lönnerdal, B. (2009). Nutritional roles of lactoferrin. Current opinion in clinical 
nutrition and metabolic care 12, 293-7.  
LʼHocine, L. (2000). Purification and partial characterization of 
fructosyltransferase and invertase from Aspergillus niger AS0023. Journal of 
Biotechnology 81, 73-84.  
Mandalari, G., Bennett, R. N., Kirby, A. R., Lo Curto, R. B., Bisignano, G., 
Waldron, K. W., and Faulds, C. B. (2006). Enzymatic hydrolysis of flavonoids 
and pectic oligosaccharides from bergamot (Citrus bergamia Risso) peel. 
Journal of agricultural and food chemistry 54, 8307-13.  
Manderson, K., Pinart, M., Tuohy, K. M., Grace, W. E., Hotchkiss, A. T., Widmer, 
W., Yadhav, M. P., Gibson, G R, and Rastall, R A (2005). In vitro 
determination of prebiotic properties of oligosaccharides derived from an 
orange juice manufacturing by-product stream. Applied and environmental 
microbiology 71, 8383-9.  
40 
 
Masson, P., and Heremans, J. (1971). Lactoferrin in milk from different species. 
Comparative Biochemistry and Physiology Part B: Biochemistry and 
Molecular Biology 39, 119-IN13.  
Menne, E., and Guggenbuhl, N. (2000). Fn-type Chicory Inulin Hydrolysate Has a 
Prebiotic Effect in Humans. J. Nutr. 130, 1197-1199.  
Miller, J. B., Bull, S., Miller, J., and McVeagh, P. (1994). The oligosaccharide 
composition of human milk: temporal and individual variations in 
monosaccharide components. Journal of pediatric gastroenterology and 
nutrition 19, 371-6.  
Minke, R., and Blackwell, J. (1978). The structure of chitin. Journal of Molecular 
Biology 120, 167-181.  
Mittal, R., Wang, Y., Hunter, C. J., Gonzalez-Gomez, I., and Prasadarao, N. V. 
(2009). Brain damage in newborn rat model of meningitis by Enterobacter 
sakazakii: a role for outer membrane protein A. Laboratory investigation; a 
journal of technical methods and pathology 89, 263-77. 
Molis, C., Flourie, B, Ouarne, F., Gailing, M., Lartigue, S., Guibert, A., Bornet, F, 
and Galmiche, J. (1996). Digestion, excretion, and energy value of 
fructooligosaccharides in healthy humans. Am J Clin Nutr 64, 324-328.  
Moro, G., Minoli, I., Mosca, M., Fanaro, S., Jelinek, J., Stahl, B, and Boehm, G. 
(2002). Dosage-related bifidogenic effects of galacto- and 
41 
 
fructooligosaccharides in formula-fed term infants. Journal of pediatric 
gastroenterology and nutrition 34, 291-5.  
Mullane, N. R., Drudy, D., Whyte, P., O ʼMahony, M., Scannell, A. G. M., Wall, P. 
G., and Fanning, S. (2006). Enterobacter sakazakii: biological properties and 
significance in dried infant milk formula (IMF) powder+. International Journal 
of Dairy Technology 59, 102-111.  
Muytjens, H. L., Zanen, H. C., Sonderkamp, H. J., Kollee, L. A., Wachsmuth, I. 
K., and Farmer, J. J. (1983). Analysis of eight cases of neonatal meningitis 
and sepsis due to Enterobacter sakazakii. J. Clin. Microbiol. 18, 115-120.  
Naidu, S. S., Erdei, J., CzirÓK, É., Kalfas, S., GadÓ, I., ThorÉN, A., Forsgren, A., 
and Naidu, A. S. (1991). Specific binding of lactoferrin to Escherichia coli 
isolated from human intestinal infections. APMIS 99, 1142-1150.  
Neeser, J. R., Koellreutter, B., and Wuersch, P. (1986). Oligomannoside-type 
glycopeptides inhibiting adhesion of Escherichia coli strains mediated by 
type 1 pili: preparation of potent inhibitors from plant glycoproteins. Infect. 
Immun. 52, 428-436.  
Newburg, D S (2000). Oligosaccharides in human milk and bacterial colonization. 
Journal of pediatric gastroenterology and nutrition 30 Suppl 2, S8-17.  
Newburg, David S, Ruiz-Palacios, G. M., Altaye, M., Chaturvedi, P., Meinzen-
Derr, J., Guerrero, M. de L., and Morrow, A. L. (2004). Innate protection 
42 
 
conferred by fucosylated oligosaccharides of human milk against diarrhea in 
breastfed infants. Glycobiology 14, 253-63.  
Ninonuevo, M. R. et al. (2006). A strategy for annotating the human milk 
glycome. Journal of agricultural and food chemistry 54, 7471-80.  
Ochoa, T. J., Noguera-Obenza, M., Ebel, F., Guzman, C. A., Gomez, H. F., and 
Cleary, T. G. (2003). Lactoferrin Impairs Type III Secretory System Function 
in Enteropathogenic Escherichia coli. Infection and Immunity 71, 5149-5155.  
Ochoa, Theresa J, and Cleary, Thomas G (2009). Effect of lactoferrin on enteric 
pathogens. Biochimie 91, 30-4.  
Ofek, I., Hasty, D.L, and Doyle, R. (2003) Bacterial Adhesion to Animal Cells and 
Tissues. ASM Press. 
Ofek, Itzhak, and Beachey, E. H. (1978). Mannose Binding and Epithelial Cell 
Adherence of Escherichia coli. Infect. Immun. 22, 247-254.  
Olano-Martin, E., Gibson, G.R., and Rastall, R.A. (2002). Comparison of the in 
vitro bifidogenic properties of pectins and pectic-oligosaccharides. Journal of 
Applied Microbiology 93, 505-511.  
Olano-Martin, Estibaliz, Williams, M. R., Gibson, Glenn R, and Rastall, Robert A 
(2003). Pectins and pectic-oligosaccharides inhibit Escherichia coli O157:H7 
Shiga toxin as directed towards the human colonic cell line HT29. FEMS 
Microbiology Letters 218, 101-105.  
43 
 
Old, D. C. (1972). Inhibition of the Interaction Between Fimbrial Haemagglutinins 
and Erythrocytes by D-Mannose and Other Carbohydrates. Microbiology 71, 
149-157.  
Orsi, Nicola (2004). The antimicrobial activity of lactoferrin: Current status and 
perspectives. BioMetals 17, 189-196. 
Pagotto F.J. Nazarowec-White M. Bidawid S. Farber J.M. (2003). Enterobacter 
sakazakii: Infectivity and Enterotoxin Production In Vitro and In Vivo. Journal 
of Food Protection® 66, 6.  
Pauline P. Ward, Sonia Uribe-Luna, and O. M. C. (2002). Lactoferrin and host 
defense. Biochemistry and cell biology 80, 95-102. 
Penders, J., Thijs, C., Vink, C., Stelma, F. F., Snijders, B., Kummeling, I., Brandt, 
P. A. van den, and Stobberingh, E. E. (2006). Factors influencing the 
composition of the intestinal microbiota in early infancy. Pediatrics 118, 511-
21.  
Pinzón-Arango, P. A., Liu, Y., and Camesano, T. A. (2009). Role of cranberry on 
bacterial adhesion forces and implications for Escherichia coli-uroepithelial 
cell attachment. Journal of medicinal food 12, 259-70. 
Preter, V. de, Vanhoutte, T., Huys, G., Swings, J., Rutgeerts, P., and Verbeke, K. 
(2008). Baseline microbiota activity and initial bifidobacteria counts influence 
44 
 
responses to prebiotic dosing in healthy subjects. Alimentary pharmacology 
& therapeutics 27, 504-13.  
Qiu, J. (1998). Human milk lactoferrin inactivates two putative colonization 
factors expressed by Haemophilus influenzae. Proceedings of the National 
Academy of Sciences 95, 12641-12646.  
Quintero, M., Maldonado, M., Perez-Munoz, M., Jimenez, R., Fangman, T., 
Rupnow, J., Wittke, A., Russell, M., and Hutkins, Robert (2011). Adherence 
Inhibition of Cronobacter sakazakii to Intestinal Epithelial Cells by Prebiotic 
Oligosaccharides. Current microbiology.  
Rahbar, M., and Diba, K. (2010). In vitro activity of cranberry extract against 
etiological agents of urinary tract infections. Journal of Pharmacy and 
Pharmacology 4, 286-288. 
Raz, R., Chazan, B., and Dan, M. (2004). Cranberry juice and urinary tract 
infection. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America 38, 1413-9.  
Reddy, B. S., and Rivenson, A. (1993). Inhibitory Effect of Bifidobacterium 
longum on Colon, Mammary, and Liver Carcinogenesis Induced by 2-Amino-
3-methylimidazo[4,5-f]quinoline, a Food Mutagen. Cancer Res. 53, 3914-
3918.  
45 
 
Rhoades, J., Gibson, G., Formentin, K., Beer, M., and Rastall, R. (2006). 
Inhibition of the adhesion of enteropathogenic Escherichia coli strains to HT-
29 cells in culture by chito-oligosaccharides. Carbohydrate Polymers 64, 57-
59.  
Roberfroid, M (1993). Dietary fiber, inulin, and oligofructose: a review comparing 
their physiological effects. Critical reviews in food science and nutrition 33, 
103-48. 
Roberfroid, Marcel (2007). Prebiotics: The Concept Revisited. J. Nutr. 137, 830S-
837.  
Roberfroid, Marcel B (2000). Prebiotics and probiotics: are they functional foods? 
Am J Clin Nutr 71, 1682S-1687.  
Roode, B. M. de, Franssen, M. C. R., Padt, A. van der, and Boom, R. M. (2003). 
Perspectives for the industrial enzymatic production of glycosides. 
Biotechnology progress 19, 1391-402. 
Ruiz-Palacios, G. M., Cervantes, L. E., Ramos, P., Chavez-Munguia, B., and 
Newburg, David S (2003). Campylobacter jejuni binds intestinal H(O) 
antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of 
human milk inhibit its binding and infection. The Journal of biological 
chemistry 278, 14112-20.  
46 
 
Rycroft, C. E., Jones, M. R., Gibson, G.R., and Rastall, R.A. (2001). A 
comparative in vitro evaluation of the fermentation properties of prebiotic 
oligosaccharides. Journal of Applied Microbiology 91, 878-887.  
Saavedra, J. (1994). Feeding of Bifidobacterium bifidum and Streptococcus 
thermophilus to infants in hospital for prevention of diarrhoea and shedding 
of rotavirus. The Lancet 344, 1046-1049.  
Sako, T. (1999). Recent progress on research and applications of non-digestible 
galacto-oligosaccharides. International Dairy Journal 9, 69-80.  
Salit, I. E. (1977). Hemagglutination by purified type I Escherichia coli pili. Journal 
of Experimental Medicine 146, 1169-1181.  
Saulnier, D. M. A., Spinler, J. K., Gibson, Glenn R, and Versalovic, James 
(2009). Mechanisms of probiosis and prebiosis: considerations for enhanced 
functional foods. Current opinion in biotechnology 20, 135-41.  
Savage, T., Cotter, P., and Zakrzewska, E. (1996). The effect of feeding a 
mannanoligosaccharide on immunoglobulin plasma IgA and bile IgA of 
Wrolstad MW male turkeys. Poultry Sci 75, 143. 
Schoeni, J. L., and Wong, A. C. (1994). Inhibition of Campylobacter jejuni 
colonization in chicks by defined competitive exclusion bacteria. Appl. Envir. 
Microbiol. 60, 1191-1197.  
47 
 
Searle, L. E. J. et al. (2009). A mixture containing galactooligosaccharide, 
produced by the enzymic activity of Bifidobacterium bifidum, reduces 
Salmonella enterica serovar Typhimurium infection in mice. Journal of 
medical microbiology 58, 37-48.  
Sekine, K., Toida, T., Saito, M., Kuboyama, M., Kawashima, Takuji, and 
Hashimoto, Y. (1985). A New Morphologically Characterized Cell Wall 
Preparation (Whole Peptidoglycan) from Bifidobacterium infantis with a 
Higher Efficacy on the Regression of an Established Tumor in Mice. Cancer 
Res. 45, 1300-1307. 
Shahriar, F., Gordon, J. R., and Simko, E. (2006). Identification of 
lipopolysaccharide-binding proteins in porcine milk. Canadian journal of 
veterinary research = Revue canadienne de recherche vétérinaire 70, 243-
50.  
Shane, S. M., Lyons, T. P., and Jacques, K. A. (2001). Mannan oligosaccharides 
in poultry nutrition: mechanisms and benefits. 65-77.  
Sharon, Nathan (2006). Carbohydrates as future anti-adhesion drugs for 
infectious diseases. Biochimica et biophysica acta 1760, 527-37.  
Sharon, Nathan, and Ofek, Itzhak (2002). Fighting infectious diseases with 
inhibitors of microbial adhesion to host tissues. Critical reviews in food 
science and nutrition 42, 267-72.  
48 
 
Sharon, Nathan, and Ofek, Itzhak (2000). Safe as mother ʼs milk: Carbohydrates 
as future anti-adhesion drugs for bacterial diseases (Springer Netherlands)  
Shmuely, H. et al. (2004). Susceptibility of Helicobacter pylori isolates to the 
antiadhesion activity of a high-molecular-weight constituent of cranberry. 
Diagnostic microbiology and infectious disease 50, 231-5.  
Shoaf, K., Mulvey, G. L., Armstrong, G. D., and Hutkins, R. W. (2006). Prebiotic 
galactooligosaccharides reduce adherence of enteropathogenic Escherichia 
coli to tissue culture cells. Infection and immunity 74, 6920-8.  
Shoaf-Sweeney, K. D., and Hutkins, R. W. (2008). Advances in Food and 
Nutrition Research Volume 55 (Elsevier)  
Silk, D. B. A., Davis, A., Vulevic, J, Tzortzis, G, and Gibson, G R (2009). Clinical 
trial: the effects of a trans-galactooligosaccharide prebiotic on faecal 
microbiota and symptoms in irritable bowel syndrome. Alimentary 
pharmacology & therapeutics 29, 508-18.  
Sims, M., Dawson, K., Newman, K., Spring, P., and Hoogell, D. (2004). Effects of 
dietary mannan oligosaccharide, bacitracin methylene disalicylate, or both 
on the live performance and intestinal microbiology of turkeys. Poult. Sci. 83, 
1148-1154.  
49 
 
Sinclair, H. R., Slegte, J. de, Gibson, Glenn R, and Rastall, Robert A (2009). 
Galactooligosaccharides (GOS) inhibit Vibrio cholerae toxin binding to its 
GM1 receptor. Journal of agricultural and food chemistry 57, 3113-9.  
Sobota, A. E. (1984). Inhibition of bacterial adherence by cranberry juice: 
potential use for the treatment of urinary tract infections. The Journal of 
urology 131, 1013-6.  
Spais, A. B., Giannenas, I. A., Florou-Paneri, P., Christaki, E., and Botsoglou, N. 
A. (2003). Effect of the feed supplement Bio-Mos, a mannan-
oligosaccharide, on the performance of broiler chickens (In Greek and 
English). Journal of the Hellenic Veterinary Medical Society 54, 8.  
Spiller, G. A., Chernoff, M. C., Hill, R. A., Gates, J. E., Nassar, J. J., and Shipley, 
E. A. (1980). Effect of purified cellulose, pectin, and a low-residue diet on 
fecal volatile fatty acids, transit time, and fecal weight in humans. The 
American journal of clinical nutrition 33, 754-9.  
Spring, P., Wenk, C., Dawson, K., and Newman, K. (2000). The effects of dietary 
mannaoligosaccharides on cecal parameters and the concentrations of 
enteric bacteria in the ceca of salmonella-challenged broiler chicks. Poult. 
Sci. 79, 205-211.  
Stark, P. L., and Lee, A. (1982). The Microbial Ecology of the Large Bowel of 
Breastfed and Formula-fed Infants During the First Year of Life. Journal of 
Medical Microbiology 15, 189-203.  
50 
 
Steinberg, D., Feldman, M., Ofek, Itzhak, and Weiss, E. I. (2005). Cranberry high 
molecular weight constituents promote Streptococcus sobrinus desorption 
from artificial biofilm. International journal of antimicrobial agents 25, 247-51.  
Steinberg, D., Feldman, M., Ofek, Itzhak, and Weiss, E. I. (2004). Effect of a 
high-molecular-weight component of cranberry on constituents of dental 
biofilm. The Journal of antimicrobial chemotherapy 54, 86-9.  
Teuri, U., and Korpela, R. (1998). Galacto-oligosaccharides relieve constipation 
in elderly people. Annals of nutrition & metabolism 42, 319-27.  
Tojo, M., Oikawa, T., Morikawa, Y., Yamashita, N., Iwata, S., Satoh, Y., Hanada, 
J., and Tanaka, R. (1987). The Effects of Bifidobacterium breve 
Administration on Campylobacter Enteritis. Pediatrics International 29, 160-
167.  
Torres, D. P. M., Gonçalves, M. do P. F., Teixeira, J. A., and Rodrigues, L. R. 
(2010). Galacto-Oligosaccharides: Production, Properties, Applications, and 
Significance as Prebiotics - Torres - 2010 - Comprehensive Reviews in Food 
Science and Food Safety - Wiley Online Library. Comprehensive Reviews in 
Food Science and Food Safety 9, 438-454.  
Tuohy, K. M., Kolida, S, Lustenberger, A. M., and Gibson, G R (2001). The 
prebiotic effects of biscuits containing partially hydrolysed guar gum and 
fructo-oligosaccharides--a human volunteer study. The British journal of 
nutrition 86, 341-8.  
51 
 
Valenti, P., and Antonini, G. (2005). Lactoferrin: an important host defence 
against microbial and viral attack. Cellular and molecular life sciences : 
CMLS 62, 2576-87.  
Vázquez, M. (2000). Xylooligosaccharides: manufacture and applications. Trends 
in Food Science & Technology 11, 387-393.  
Weir, E. (2002). Powdered infant formula and fatal infection with Enterobacter 
sakazakii. CMAJ : Canadian Medical Association journal = journal de 
lʼAssociation medicale canadienne 166, 1570.  
Weis, W. I., and Drickamer, K. (1996). Structural basis of lectin-carbohydrate 
recognition. Annual review of biochemistry 65, 441-73.  
Weiss, E. I., Kozlovsky, A., Steinberg, D., Lev-Dor, R., Bar Ness Greenstein, R., 
Feldman, M., Sharon, Nathan, and Ofek, Itzhak (2004). A high molecular 
mass cranberry constituent reduces mutans streptococci level in saliva and 
inhibits in vitro adhesion to hydroxyapatite. FEMS microbiology letters 232, 
89-92.  
Weizman, Z., Asli, G., and Alsheikh, A. (2005). Effect of a probiotic infant formula 
on infections in child care centers: comparison of two probiotic agents. 
Pediatrics 115, 5-9. 
Willats, W. (2000). Making and using antibody probes to study plant cell walls. 
Plant Physiology and Biochemistry 38, 27-36.  
52 
 
Williams, C. H., Witherly, S. A., and Buddington, R. K. Influence of dietary 
neosugar on selected bacterial groups of the human faecal microbiota. 
Microbial ecology in health and disease 7, 91-97. 
Wilson, M. L., and Gaido, L. (2004). Laboratory Diagnosis of Urinary Tract 
Infections in Adult Patients. Clinical Infectious Diseases 38, 1150 - 1158.  
Xia, W., Liu, P., Zhang, Jiali, and Chen, J. (2011). Biological activities of chitosan 
and chitooligosaccharides. Food Hydrocolloids 25, 170-179.  
Yamauchi, K., Tomita, M., Giehl, T. J., and Ellison, R. T. (1993). Antibacterial 
activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. 
Infect. Immun. 61, 719-728.  
Yamazaki, S., Machii, K., Tsuyuki, S., Momose, H., Kawashima, T, and Ueda, K. 
(1985). Immunological responses to monoassociated Bifidobacterium 
longum and their relation to prevention of bacterial invasion. Immunology 56, 
43-50.  
Zafriri, D., Ofek, I, Adar, R., Pocino, M., and Sharon, N (1989). Inhibitory activity 
of cranberry juice on adherence of type 1 and type P fimbriated Escherichia 
coli to eucaryotic cells. Antimicrobial agents and chemotherapy 33, 92-8.  
Zampa, A., Silvi, S., Fabiani, R., Morozzi, G., Orpianesi, C., and Cresci, A. 
(2004). Effects of different digestible carbohydrates on bile acid metabolism 
53 
 
and SCFA production by human gut micro-flora grown in an in vitro semi-
continuous culture. Anaerobe 10, 19-26.  
Ziegler, E., Vanderhoof, J. A., Petschow, B., Mitmesser, S. H., Stolz, S. I., Harris, 
C. L., and Berseth, C. L. (2007). Term infants fed formula supplemented with 
selected blends of prebiotics grow normally and have soft stools similar to 
those reported for breast-fed infants. Journal of pediatric gastroenterology 
and nutrition 44, 359-64. 
Zivkovic, A. M., German, J. B., Lebrilla, C. B., and Mills, D. A. (2010). Microbes 
and Health Sackler Colloquium: Human milk glycobiome and its impact on 
the infant gastrointestinal microbiota. Proceedings of the National Academy 
of Sciences 108:4653-8. 
 
 
 
 
 
 
 
 
 
54 
 
 
 
 
 
 
 
 
Chapter 2 
Adherence Inhibition of Cronobacter sakazakii to intestinal epithelial cells 
by  prebiotic oligosaccharides. 
 
 
 
 
 
 
 
 
 
 
55 
 
Adherence Inhibition of Cronobacter sakazakii to intestinal epithelial cells 
by  prebiotic oligosaccharides. 
 
M. I. Quintero1, M.X. Maldonado1, M.E. Perez1, J. Rupnow1, R. Jimenez1, T. 
Fangman2, M. Russell3, and R. Hutkins1 
 
1Department of Food Science and Technology, University of Nebraska - Lincoln 
 2Center of Biotechnology, University of Nebraska - Lincoln 
3 Mead Johnson Nutrition, Evansville, Indiana 
 
Correspondence to Robert Hutkins, University of Nebraska, Department of Food 
Science and Technology, 338 FIC, Lincoln, NE  68583-0919.  Phone: 402-472-
2820.  Fax: 402-472-1693.  E-mail: rhutkins1@unl.edu. 
 
KEYWORDS:  Cronobacter sakazakii, Enterobacter sakazakii, 
galactoligosaccharides, polydextrose, prebiotics, adherence  
 
 
 
56 
 
Abstract 
Cronobacter sakazakii is an opportunistic pathogen that has been implicated in 
meningitis, NEC, and sepsis in neonates. Colonization and subsequent infection 
and invasion of C. sakazakii require that the organism adhere to host cell 
surfaces.  Agents that inhibit or block attachment of the pathogen to epithelial 
cells could be useful in reducing infections.  The goal of this research was to 
assess the ability of prebiotic galactooligosaccharides (GOS) and polydextrose 
(PDX) to inhibit adherence of C. sakazakii 4603 to a HEp-2 human cell line.  
Adherence experiments were performed in the presence or absence of prebiotics 
using HEp-2 cells grown to confluency on glass coverslips. Prebiotics and 
bacteria were added and incubated for 3 hours. Coverslips were washed and 
adherence was determined by cultural and microscopic methods.  When 
measured microscopically or by cultural methods, significant reductions in 
adherence (56% and 71%, respectively) of C. sakazakii were observed in the 
presence of GOS (16 mg/ml).  Adherence inhibition also occurred (48%) when a 
GOS-PDX blend (8 mg/ml each) was tested, although PDX by itself had less 
effect.  Similar results were also observed for Caco-2 cells and also for another 
strain of C. sakazakii (29004). 
These results suggest that GOS and PDX, alone and in combination, may have 
an anti-adhesive effect on C. sakazakii and directly inhibit the adherence to 
gastrointestinal epithelial cells.
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Introduction 
Prebiotics were defined originally as food ingredients that provide beneficial 
effects for the host by selectively stimulating the growth and/or activity of one or a 
limited number of bacteria in the colon [10].  In recent years, prebiotics have 
been reported to have additional biological activities, beyond their influence on 
the gut microbiota.  Specifically, it has been suggested that some prebiotics, in 
particular, galactooligosaccharides (GOS), may be able to inhibit gastrointestinal 
infections via anti-adhesive activities [9,26,30].  This concept is based on the 
observation that for most pathogens, the initial adherence to host cell surfaces is 
one of the first steps prior to colonization and infection.  Adherence is most 
commonly mediated via lectin-like adhesins expressed by the bacteria that 
recognize and adhere to ligand-like carbohydrates located on the surface of the 
host epithelial cells.  Bacterial variants that are unable to express functional 
adhesins are unable to adhere and initiate infections, indicating that adherence is 
required for pathogenesis [1,4,14].  Thus, agents that inhibit adherence could 
potentially reduce infections [29,35]. 
The anti-adherence strategy depends on the structural similarity between the 
carbohydrate binding sites ordinarily recognized by pathogens and the 
exogenous prebiotic oligosaccharides.  The latter would compete with the 
cognate sugars for binding to the adhesin and thereby inhibit bacterial adherence 
[27,30].  Indeed, in human milk there are many oligosaccharides that contain 
residues and linkages similar to those found on the surface of intestinal epithelial 
cells [18,28].  These human milk oligosaccharides (HMO) have high affinity for 
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bacterial adhesins, which likely contribute to the anti-adherence properties of 
human milk.  Several recent studies have reported that food-grade 
oligosaccharides that are currently marketed as prebiotics, also have anti-
adhesive activity [27,31,32].  In these studies, food-grade forms of GOS inhibited 
adherence of Eschericia coli and Salmonella enterica serovar Typhimurium to the 
surface of tissue culture cells and also inhibited Vibrio cholerae toxin binding to 
the cell surface toxin receptors.  Commercial GOS is comprised of several 
galactose-containing species of varying lengths, and although this GOS lacks 
sialic acid and other functional groups ordinarily present in human milk 
oligosaccharides, at sufficient concentrations they nonetheless have adherence 
inhibition activity [31].  Another commercial carbohydrate that has been proposed 
to have prebiotic activity is polydextrose (PDX), a polysaccharide composed of 
randomly cross-linked glucose units [23].  PDX resists small bowel enzymes and 
is fermented more slowly by intestinal bacteria versus other non-digestible 
oligosaccharides [25]. Its anti-adhesive activity, however, has not yet been 
studied. 
Cronobacter sakazakii (formerly Enterobacter sakazakii) is now recognized as an 
emerging opportunistic pathogen and has been implicated in severe forms of 
meningitis, necrotizing enterocolitis (NEC), and sepsis in neonates [3,16,24].  
The infant mortality rate due to infection by this organism has been reported to 
be 33 – 80%, with up to 20% of surviving neonates developing serious 
neurological complications [19].  Therefore, prophylactic efforts to mitigate 
neonatal infections caused by this organism are of considerable interest [11,12].  
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The main goal of this research, therefore, was to assess the ability of 
galactooligosaccharide (GOS) and polydextrose (PDX), as well as a blend of 
GOS and PDX, to inhibit adherence of C. sakazakii to a human cell line.   
Materials and Methods 
Organisms and growth conditions. Strains of C. sakazakii used in this study 
are described in Table 1 and were obtained from K. Venkitanarayanan 
(Department of Animal Science, University of Connecticut).  Prior to each 
experiment, frozen stock cultures of each organism were thawed, plated onto 
Tryptic Soy Agar (TSA; Difco) and grown overnight at 37°C.  A single colony was 
inoculated into 10 ml of Tryptic Soy Broth (TSB; Difco) and incubated aerobically, 
without shaking.  Preliminary experiments revealed that adherence rates were 
highest when cells were in late log phase.  Therefore, after 6 hour incubation, 
cultures were harvested by centrifugation (3,184 x g for 8 minutes).  The cells 
were washed once with phosphate-buffered saline (PBS) and re-suspended in 
minimal essential medium (MEM; Hyclone, Logan, Utah), supplemented with 
10% fetal bovine serum (FBS; Hyclone).  Minimal essential medium was pre-
equilibrated at tissue culture conditions (5% CO2, 95% relative humidity, 37°C).  
Based on additional preliminary experiments, two strains (4603 and 29004) 
repeatedly gave the highest adherence rates on HEp-2 cells and were used for 
all subsequent experiments. 
Prebiotics (GOS and PDX).  Galactooligosaccharide (GOS; Friesland Foods 
DOMO, Zwolle, the Netherlands) was obtained as a 70% concentrated syrup and 
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was lyophilized to give a final product of 95% total solids.  The GOS 
concentration, based on the manufacturer’s information, was 60% (containing 
mainly chains of 3-6 monomers in the ∃1-4 form), with the balance as lactose, 
glucose, and galactose.  Polydextrose (PDX), obtained from Danisco (New 
Century, KS), had an average degree of polymerization (DP) of 12 and an 
average molecular weight of 2000 [7].  The GOS and PDX were prepared as 
concentrated stock solutions with distilled sterile water at a final concentration of 
160 mg/ml.  The solutions were filter sterilized using 0.22 µm filters.  A 1:1 blend 
of PDX and GOS was prepared by mixing equal volumes to give 80 mg/ml of 
each. 
Tissue culture cells.  HEp-2 cells were obtained from the American Type 
Culture Collection (ATCC; Manassas, Virginia).  Cells were grown in 75 cm2 
tissue culture flasks (Corning) containing 25 ml of MEM supplemented with 10% 
FBS in a CO2 incubator at tissue culture conditions.  Confluent Hep-2 cells were 
harvested by adding 0.5 ml of 0.25% Trypsin-EDTA Solution (Sigma) and 
incubating for 15 minutes at tissue culture conditions.  Trypsin was inactivated 
with 0.5 ml of FBS. Cells were then seeded onto 12-mm diameter glass 
coverslips in 24-well tissue culture plates (Falcon) at approximately 3.6 x 105 
viable cells per well, and 500 µl of MEM supplemented with 10% FBS was added 
to each well.  Plates were incubated under tissue culture conditions for two days 
prior to the start of each experiment, or until confluency was reached.  Media was 
replaced one day before the experiment.  Caco-2 cells (ATCC) were grown as for 
HEp-2 cells except that the MEM was supplemented with 20% FBS.  and the 
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cells were incubated for fourteen days prior to the start of each experiment, or 
until confluency was reached.  Media was replaced every other day and one day 
before the experiment. 
Adherence Assays. Cell suspensions of C. sakazakii 4603 and ATCC 29004 for 
HEp-2 cells, and C. sakazakii ATCC 29004 for Caco-2 cells, were prepared as 
described above.  Prebiotics were mixed with bacterial cultures (in MEM 
supplemented with FBS) prior to addition to the tissue culture cells.  As a control, 
water was added to the bacterial cultures at the same volume as the prebiotics.  
The prebiotic solutions represented 10% of the final volume of the suspension, 
giving a final concentration of 16 mg/ml of prebiotic in the assay mixtures.  For 
the GOS-PDX blend, the final concentration of each prebiotic was 8 mg/ml. The 
plates were incubated for 3 hours at tissue culture conditions. Preliminary 
experiments indicated that 3 hours of incubation were optimal for adherence of 
the bacterial strains to the HEp-2 and Caco-2 tissue culture.  The wells were then 
washed 5 times with PBS to remove non-adhered bacterial cells.  HEp-2 
experiments were done in duplicate and replicated 5 times (n = 10) for 
microscopic analyses and 3 times (n = 6) for cultural enumeration.  The Caco-2 
experiments were done in duplicate and replicated twice (n=4).   
Microscopic enumeration.  Adhered cells were fixed with 100% methanol for 20 
minutes and stained with 10% Geimsa for 15 minutes.  The slides were then 
washed once with sterile distilled water and dried overnight at room temperature.  
Coverslips were mounted on microscope slides and observed under a phase 
contrast microscope with the 100x objective. Fifteen pictures of each coverslip 
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were taken using Motic Image software following an established pattern 
throughout the entire coverslip.  The number of cells and bacteria in each picture 
were counted using Image J image analysis software.  Total adherence was 
calculated as the number of adhered bacteria per tissue culture   cell.  Adherence 
inhibition was calculated as the number of adhered bacteria per cell in the control 
minus the number of adhered bacteria per cell in the treatment divided by the 
number of adhered bacteria per cell in the control. 
Culture enumeration.  Cells were washed as described above and detached by 
addition of 0.1% Triton X-100 for 30 minutes at room temperature.  The cells 
were collected and enumerated on Tryptic Soy Agar (TSA; Difco) after aerobic 
incubation at 37°C for 24 hours.  Adherence inhibition was calculated as the 
number of adhered bacteria per ml in the control minus the number of adhered 
bacteria per ml in the treatment divided by the number of adhered bacteria per ml 
in the control. 
Statistical Analysis. Significant differences between the treatments were 
determined by analysis of variance (ANOVA) using PROC GLIMMIX in SAS 
(version 9.2). 
Results 
GOS and PDX reduce adherence of C. sakazakii to HEp-2 cells Adherence 
assays were conducted for all five strains of C. sakazakii on both cell lines (HEp-
2 and Caco-2).  As other workers previously reported [20], we also observed that 
some strains had higher adherence rates than others.  Specifically, preliminary 
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experiments (data not shown) showed that strains 4603 and 29004 gave the 
most consistent results and were used for these studies.  Subsequently, 
adherence of C. sakazakii 4603 to HEp-2 cells in the presence and absence of 
prebiotics was measured by microscopic and culture methods.  Both methods 
revealed that C. sakazakii 4603 adherence was significantly reduced when GOS 
and the GOS-PDX blend was present (Figure 1).  By microscopic examination, 
GOS addition led to a 56% reduction of binding by C. sakazakii 4603 to the HEp-
2 cells.  Similarly, a 48% reduction occurred in the presence of the GOS-PDX 
blend.  However, PDX by itself did not significantly reduce adherence, when 
measured by microscopy (Figure 1A).  Experiments with C. sakazakii ATCC 
29004 gave similar results when measured microscopically, with reductions of 
63% and 53% in the presence of GOS and the GOS-PDX blend, respectively, 
(Figure 2).  However, for this strain, the PDX significantly inhibited (42%) 
adherence. 
The cultural enumeration results confirmed those observed by microscopic 
examination for both strains (Figures 1B and 2B).  However, inhibition levels 
were somewhat higher when the culture data was used to calculate adherence 
inhibition.  For strain 4603, GOS and the GOS-PDX blend reduced adherence by 
71% and 49%, respectively.  PDX also inhibited adherence by 55%.  The GOS, 
GOS-PDX, and PDX treatments reduced adherence of strain 29004 by 83%, 
80%, and 58%, respectively.  Photomicrographs of the coverslips provided 
additional confirmation that adherence of C. sakazakii to HEp-2 cells was 
reduced in the presence of GOS, PDX and the GOS-PDX blend (Figure 3). 
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GOS and the GOS-PDX blend also inhibit adherence of C. sakazakii to 
Caco-2 cells.  Adherence of C. sakazakii ATCC 29004 to Caco-2 cells in the 
presence and absence of prebiotics was measured by microscopic methods 
(Figure 4). These experiments revealed that C. sakazakii 29004 adherence was 
significantly lower when the GOS or GOS-PDX blend was present (31 and 38% 
reductions, respectively).  Although a 20% reduction in adherence was observed 
for the PDX treatment, this reduction was not significant. 
Discussion 
The use of molecular decoys to reduce pathogen adherence to intestinal 
epithelial cells and subsequently prevent infection by pathogenic agents was 
proposed more than a decade ago [35].  However, only recently have food-grade 
oligosaccharides, including those already used as prebiotics, been shown to 
have anti-adhesive activity against enteric pathogens [27,31].  In these reports, 
enteropathogenic E. coli and Salmonella enterica serovar Typhimurium were 
inhibited in vitro and in mice by two different forms of GOS.  These reports led us 
to consider whether adherence inhibition by prebiotics extended to other enteric 
pathogens, and C. sakazakii, in particular.  Although the prevalence of C. 
sakazakii in the environment and in foods is very low and infections are rare, the 
morbidity rates are very high [8,15].  Therefore, efforts aimed at reducing 
infections are warranted. 
In this study, adherence inhibition of C. sakazakii to HEp-2 cells in the presence 
of prebiotic carbohydrates was determined by two methods, direct microscopic 
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counting and by cultural enumeration on agar plates.  By both methods, the 
results showed that GOS had an anti-adhesive effect on both of the strains of C. 
sakazakii used in these experiments.  The GOS used in these experiments also 
contained lactose, glucose, and galactose; however, their contribution to 
adherence was likely not significant, based on previous reports [5,21,31].  
Although PDX also had anti-adherence activity, the effects were not significant in 
all experiments (Figure 1A).  In previous experiments, GOS had greater 
adherence inhibition compared to all other tested oligosaccharides [31].  
Similarly, in the experiments with Caco-2 cells, the adherence inhibition of C. 
sakazakii 29004 by GOS was greater than PDX and equal to that of the blend.  
Although the pathogenesis of C. sakazakii is still under investigation, it appears 
to share the same initial steps in infection as other pathogens by adhering and 
colonizing host surfaces [20,22].  It was previously suggested that this organism 
adheres to host cell tissue by recognizing specific host cell targets [22], indicating 
that an anti-adherence approach could be useful.  However, adherence in C. 
sakazakii was also suggested to be independent of fimbrae [20]. 
This is the first study in which PDX was compared to GOS in an anti-adherence 
model.  Previously, an in vitro analysis suggested that GOS is fermented 
primarily in the proximal end of the large intestine, whereas PDX fermentation 
occurs from the proximal to the distal end [13,25].  The fermentation of PDX 
resulted in lower levels of short chain fatty acids (SCFA) compared to GOS, 
suggesting that PDX may be less bifidogenic.  In another in vitro study, PDX 
resulted in lower E. coli counts, compared to other prebiotics, although the 
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mechanism was not determined [33].  In adults, consumption of PDX improved 
bowel functions, produced SCFAs, and promoted the proliferation of a favorable 
intestinal microbiota [17].  Similarly, in an infant feeding trial with GOS and PDX, 
the stool characteristics of infants receiving the prebiotic mixture were more 
similar to those of breast-fed infants, in comparison to infants fed 
unsupplemented formula [34].  
Our results showed that PDX inhibited adherence of C. sakazakii on HEp-2 cells, 
although it was generally less inhibitory than GOS, at the same concentration.  
On Caco-2 cells, the PDX-GOS blend, each at 8 mg/mL, was as inhibitory as the 
GOS alone (at 16 mg/mL), suggesting that additional research on the anti-
adherence properties of PDX might be warranted.   Mange et al. [20] examined 
the adherence properties of 50 C. sakazakii strains on three cell lines, including 
HEp-2 and Caco-2 and reported that considerable heterogeneity existed within 
strains.  While mannose reduced diffuse adherence, cluster-mediated adherence 
was unaffected.  Thus, the specific means by which adherence occurred could 
not be established.  Apart from the differences between cells lines, the 
adherence inhibition results seen in our study are also likely due to structural 
differences between the galactose-containing GOS and the glucose-containing 
PDX.  
Conclusions 
Collectively, our results showed that GOS and GOS-PDX blends effectively 
reduced adherence of C. sakazakii in tissue culture experiments.  Although GOS 
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is chemically distinct from the human milk oligosaccharides that might be 
expected to have even greater adherence inhibition [2,18,28], there is evidently 
enough similarity between GOS and human milk oligosaccharides to be effective 
at the concentrations used in this study.  Consequently, in vivo supplementation 
with GOS or GOS-PDX blends might parallel some of the functionalities of these 
milk oligosaccharides. However, it should be noted that the concentration of 
prebiotics used in this in vitro study exceeds the supplementation level generally 
reported for commercial infant formula [6]. 
Acknowledgements 
This work was funded by Mead Johnson Nutrition.  We are grateful to Dr. K. 
Venkitanarayanan, Department of Animal Science, University of Connecticut, for 
kindly providing us with strains of C. sakazakii.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
References 
1. Boddicker JD, Ledeboer NA, Jagnow J, et al. (2002) Differential binding 
to and biofilm formation on, HEp-2 cells by Salmonella enterica 
serovar Typhimurium is dependent upon allelic variation in the fimH 
gene of the fim gene cluster. Mol Microbiol  45:1255-1265. 
2. Boehm G, Stahl B (2007) Oligosaccharides from milk. J Nutr  137:847S-
849S. 
3. Bowen AB, Braden CR (2006) Invasive Enterobacter sakazakii disease 
in infants. Emerg Infect Dis  12:1185-1189. 
4. Cleary J, Lai L-C, Shaw RK, et al. (2004) Enteropathogenic Escherichia 
coli (EPEC) adhesion to intestinal epithelial cells: role of bundle-
forming pili (BFP), EspA filaments and intimin. Microbiology  150:527-
538. 
5. Coppa GV, Zampini L, Galeazzi T, et al. (2006) Human milk 
oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal 
pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. 
Pediatr Res 59:377-382. 
6. Fanaro S, Marten B, Bagna R, et al. (2009) Galacto-oligosaccharides 
are bifidogenic and safe at weaning: a double-blind randomized 
multicenter study. J Pediatr Gastr Nutr 48:82–8. 
69 
 
7. Flood MT, Auerbach MH, Craig SAS (2004). A review of the clinical 
toleration studies of polydextrose in food. Food Chem Toxicol 
42:1531–1542. 
8. Friedemann M (2007) Enterobacter sakazakii in food and beverages 
(other than infant formula and milk powder). Int J Food Microbiol  
116:1-10. 
9. Gibson GR, McCartney AL, Rastall RA (2005) Prebiotics and resistance 
to gastrointestinal infections. Br J Nutr  93 (Suppl 1):S31-S34. 
10. Gibson GR, Roberfroid M (1995) Dietary modulation of human colonic 
microbiota-introducing concept the concept of prebiotics. J Nutr 
125:1401-1412. 
11. Gurtler, JB, Kornacki JL, Beuchat LR (2005) Enterobacter sakazakii: A 
coliform of increased concern to infant health. Int J Food Microbiol  
104:1-34. 
12. Hammerman C, Kaplan M: Probiotics and neonatal intestinal infection. 
Curr Opinion Infect Dis 2006, 19:277-282.  
13. Hernot DC, Boileau TW, Bauer LL, et al. (2009)  In vitro fermentation 
profiles, gas production rates, and microbiota modulation as affected 
by certain fructans, galactooligosaccharides, and polydextrose. J 
Agric Food Chem  57:1354-1361. 
14. Isaacson RE (1983) Bacterial adherence to mucosal surfaces: an 
attribute of virulence. Bull Eur Physiopath Respir  19:75-80. 
70 
 
15. Iversen C, Forsythe S (2004)  Isolation of Enterobacter sakazakii and 
other Enterobacteriaceae from powdered infant formula and related 
products. Food Microbiol  21:771–776. 
16. Iversen C, Mullane N, McCardell B, et al. (2007) Cronobacter gen. nov., 
a new genus to accommodate the biogroups of Enterobacter 
sakazakii, and proposal of Cronobacter sakazakii gen. nov., comb. 
nov., Cronobacter malonaticus sp. nov., Cronobacter turicensis sp. 
nov., Cronobacter muytjensii sp. nov., Cronobacter dublinensis sp. 
nov., Cronobacter genomospecies 1, and of three subspecies, 
Cronobacter dublinensis subsp. dublinensis subsp. nov., 
Cronobacter dublinensis subsp. lausannensis subsp. nov. and 
Cronobacter dublinensis subsp. lactaridi subsp. nov. Int J Syst Evol 
Microbiol  58:1442-1447. 
17. Jie Z, Bang-Yao L, Ming-Jie X, et al. (2000) Studies on the effects of 
polydextrose intake on physiologic functions in Chinese people. Am 
J Clin Nutr  72:1503-1509. 
18. Kunz C, Rudloff S, Baier W, et al. (2000) Oligosaccharides in human 
milk: structural, functional, and metabolic aspects. Ann Rev Nutr  
20:699-722. 
19. Lai KK (2001) Enterobacter sakazakii infections among neonates, 
infants, children, and adults: case reports and a review of the 
literature. Medicine (Baltimore) 80:113–22 
71 
 
20. Mange JP, Stephan R, Borel N, et al. (2006) Adhesive properties 
of Enterobacter sakazakii to human epithelial and brain 
microvascular endothelial cells. BMC Microbiol  6:58-62. 
21. Martín-Sosa S, Martín MJ, Hueso P (2002) The sialylated fraction of 
milk oligosaccharides is partially responsible for binding to 
enterotoxigenic and uropathogenic Escherichia coli human strains. J 
Nutr  132:3067-3072. 
22. Mohan Nair MK, Venkitanarayanan KS (2007) Role of Bacterial OmpA 
and host cytoskeleton in the invasion of human intestinal epithelial 
cells by Enterobacter sakazakii. Pediatr Res  62:664-669. 
23. Oliveira RPS, Florence ACR, Silva RC, et al. (2009) Effect of different 
prebiotics on the fermentation kinetics, probiotic survival and fatty 
acids profiles in nonfat symbiotic fermented milk International. J 
Food Microbiol  128:467-472. 
24. Petrosyan M, Guner YS, Williams M, et al. (2009) Current concepts 
regarding the pathogenesis of necrotizing enterocolitis Pediatr Sur Int  
25:309–318. 
25. Probert HM, Apajalahti JH, Rautonen N, et al. (2004) Polydextrose, 
lactitol, and fructo-oligosaccharide fermentation by colonic bacteria 
in a three-stage continuous culture system Appl Environ Microbiol  
70:4505-4511. 
72 
 
26. Saulnier DMA, Spinler JK, Gibson GR, et al. (2009) Mechanisms of 
probiosis and prebiosis: considerations for enhanced functional 
foods. Curr Opinion Biotechnol  20:135–141. 
27. Searle LEJ, Best A, Nunez A, et al. (2009) A mixture containing 
galactooligosaccharide, produced by the enzymic activity of 
Bifidobacterium bifidum, reduces Salmonella enterica serovar 
Typhimurium infection in mice. J Med Microbiol  58:37-48 
28. Sharon N, Ofek I (2000) Safe as mother's milk: carbohydrates as 
future anti-adhesion drugs for bacterial diseases. Glycoconj J  17:659-
664. 
29. Sharon N, Ofek I (2002) Fighting infectious diseases with inhibitors of 
microbial adhesion to host tissues. Crit Rev Food Sci Nutr  42: 267-
272. 
30. Shoaf-Sweeney K, Hutkins RW (2009) Adherence, anti-adherence, and 
oligosaccharides: preventing pathogens from sticking to the host. 
Adv Food Nutr Res  55:101-161.  
31. Shoaf K, Mulvey GL, Armstrong GD, et al. (2006) Prebiotic 
galactooligosaccharides reduce adherence of enteropathogenic 
Eschericchia coli to tissue culture cells.  Infect Immun 74:6920-6928. 
32. Sinclair HR, de Slegte J, Gibson GR, et al. (2009) 
Galactooligosaccharides (GOS) inhibit Vibrio cholerae toxin binding 
to its GM1 receptor. J  Agri Food Chem  57:3113-3119. 
73 
 
33. Vester Boler BM, Hernot DC, Boileau TW, et al. (2009) Carbohydrates 
blended with polydextrose lower gas production and short-chain 
fatty acid production in an in vitro system Nutr Res  29:631-639. 
34. Ziegler E, Vanderhoof JA, Petschow B, et al. (2007) Term infants fed 
formula supplemented with selected blends of prebiotics grow 
normally and have soft stools similar to those reported for breast-fed 
infants. J Ped Gastro Nutr  44:359–364. 
35. Zorf D, Roth S (1996) Oligosaccharides anti-infection agents. Lancet  
347:1017-1021.  
  
 
 
 
 
 
 
 
 
 
 
74 
 
Figure 1.  Adherence of C. sakazakii 4603 to Hep-2 cells in the presence of 
prebiotics (16 mg/ml).  In A, adherence was measured by microscopic counting 
(n = 10), and in B, adherence was measured by cultural enumeration (n = 6).  
Statistically significant effects (p < 0.05) are indicated by the asterisk. 
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Figure 2.  Adherence of C. sakazakii 29004 to Hep-2 cells in the presence of 
prebiotics (16 mg/ml).  In A, adherence was measured by microscopic counting 
(n = 10), and in B, adherence was measured by cultural enumeration (n = 6).  
Statistically significant effects (p < 0.05) are indicated by the asterisk. 
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Figure 3.  Adherence of C. sakazakii 4603 to Hep-2 cells in the absence (A) and 
presence of GOS (B), GOS-PDX (C); and PDX (D).  
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Figure 4.  Adherence of C. sakazakii 29004 to Caco-2 cells in the presence of 
prebiotics (16 mg/ml).  Adherence was measured by microscopic counting (n = 4) 
at 1000 x magnification.  Significant effects (versus the control) are indicated by 
the asterisk (p < 0.05). 
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Table 1. Strains and Sources 
Strain Source 
Cronobacter sakazakii 4593 Milk powder isolate (infant formula) 
Cronobacter sakazakii 4603 Milk powder isolate (infant formula) 
Cronobacter sakazakii 29004 
Cronobacter sakazakii 4583 
Cronobacter sakazakii  415 
ATCC (deposited by CDC) 
Enterocolitis isolate 
Meningitis isolate 
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Abstract 
Although prebiotic oligosaccharides are well known for their ability to modulate 
the intestinal microbiota, they have been shown to have other biological 
activities.  Specifically, oligosaccharides and plant extracts may also act as 
molecular decoys that inhibit adherence of pathogens to the surface of epithelial 
cells. The goal of this research was to assess the ability of several prebiotic 
agents, including chitooligosaccharides (COS) and mannan oligosaccharides 
derived from yeast cell walls (MOSy) and konjac root (MOSk), to inhibit 
adherence of enteropathogenic Escherichia coli (EPEC), enterohemorragic 
Escherichia coli (EHEC) and Salmonella typhimurium to a human HEp-2 cell line.  
In addition, a high molecular weight component of cranberry (CHMW) was also 
assessed for anti-adherence.  Different fractions of COS significantly reduced 
adherence of EPEC at a concentration of 16 mg/ml.  Although MOSy inhibited 
EPEC, EHEC, and S. typhumiurim, adherence inhibition was not observed for 
MOSk.  Adherence inhibition of EPEC, EHEC, and S. typhumiurim by CHMW 
was observed. These results suggest that different oligosaccharides and plant 
extracts may be promising therapeutic agents that could be added to foods in 
order to prevent or mitigate bacterial adhesion to gastrointestinal epithelial cells.  
Introduction 
Prebiotics were originally defined more than 15 years ago as “non-
digestible food ingredient(s) that beneficially affects the host by selectively 
stimulating the growth and/or activity of one or a limited number of bacteria in the 
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colon, and thus improves host health” (Gibson et al. 1995).  Although this 
definition has been modified slightly (M. Roberfroid 2007), to consider a 
substance as a prebiotic still depends on the ability of that substance to effect 
positive changes in the gut microbiota.  Recently, however, some prebiotics have 
been shown to possess another quite different biological activity that also 
contributes to the health of the host.  Specifically, certain prebiotic 
oligosaccharides are able to interfere with the adherence mechanism used by 
pathogenic bacteria to attach to the surface of target tissues, in the gut as well as 
in extraintestinal tissues (Shoaf et al. 2006; Kunz et al. 2000).  The model is 
based on the structural similarity that different oligosaccharides have to the 
receptors recognized by pathogens as binding sites.   Since adherence is the first 
and perhaps rate-limiting step in many bacterial infections, strategies based on 
preventing or inhibiting adherence could be effective at reducing infections and 
the subsequent onset of disease (Klemm et al. 2010; Bavington et al. 2005; 
Shoaf et al. 2006). 
Several commercial prebiotics have been assessed in vitro for their ability 
to inhibit pathogen adherence to epithelial cells, including inulin, 
galactooligosaccharides (GOS), and fructooligosaccharides (FOS).  In particular, 
GOS has been reported to inhibit adherence of Escherichia coli, Salmonella 
enterica serovar Typhimurium and two different strains of Cronobacter sakazakii 
to tissue culture cells (Shoaf et al. 2006; Quintero et al. 2011; McGowan et al. 
2011, manuscript in preparation).  In addition, other putative prebiotics extracted 
from plant material have also been reported to have anti-adherence activity, 
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including pectic oligosaccharides that were shown to reduce invasion of 
Campylobacter jejuni to a Caco-2 cell line (Ganan et al. 2009).   
One group of plant extracts that has long been studied for their ability to 
prevent infections are cranberry extracts.  Juices and cocktails obtained from 
cranberries have been consumed for decades with the purpose of treating and 
preventing urinary tract infections (Schaeffer et al. 2004).  The high molecular 
weight component of cranberry juice has been reported to inhibit the adhesion of 
a mannose specific Type 1 fimbriated E. coli to tissue culture cells (Zafriri et al. 
1989).  Additionally, several studies have reported that cranberry juice 
constituents inhibit adherence of Helicobacter pylori to the surface of epithelial 
cells in vitro and in vivo. (Burger et al. 2000; Burger et al. 2002; Shmuely et al. 
2004). Furthermore, cranberry has been shown to inhibit t the adhesion of oral 
bacteria such as Streptococcus mutans onto tooth surfaces (Steinberg et al. 
2005; 2004; Weiss et al. 2004). 
Infections caused by enteric pathogens are commonly treated with 
antibiotics.  Although antibiotics have been very effective at reducing mortality 
caused by bacterial infections, their use has also led to the appearance of 
resistant strains (Davies et al. 2010).  Therefore, efforts to develop new 
approaches for preventing infections are a high priority among public health 
experts. In this research, several different oligosaccharides and plant extracts 
were evaluated for their ability to inhibit adherence of selected bacterial 
pathogens to HEp-2 tissue culture cells.  
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Materials and Methods 
Organisms and growth conditions 
Enteropathogenic Escherichia coli (EPEC) EPEC strain E2348/69 (O127:H6) 
was obtained from M. Donnenberg (University of Maryland School of Medicine, 
Baltimore).  Before each experiment, frozen stock cultures of were plated onto 
Tryptic Soy Agar (TSA; Difco) and grown overnight at 37°C. A single colony was 
inoculated into 10 ml of Tryptic Soy Broth (TSB; Difco) and incubated overnight 
at 37°C without shaking. Overnight cultures were then inoculated at 1% (vol/vol) 
into Modified Eagle Medium (MEM; Hyclone) supplemented with 10% fetal 
bovine serum (FBS; Hyclone) that was pre-equilibrated at tissue culture 
conditions (5% CO2, 95% relative humidity, 37°C).  Cells were then incubated in 
MEM for 80 min at 37°C prior to the start of the experiment.  
Salmonella enterica serovar Typhimurium Before each experiment, frozen 
stock cultures of were plated onto Luria Bretani Agar (LB; Difco) and grown 
overnight at 37°C. A single colony was inoculated into 10 ml of Luria Bretani 
Broth (LB; Difco) and incubated for 23-24 hours at 37°C without shaking. 
Cultures were then washed once with phosphate buffer saline (PBS) and 
resuspended in pre-equilibrated MEM supplemented with 10% FBS. 
Enterohemorragic Escherichia coli (EHEC) EHEC strain ATCC 43888 
(O157:H7) was obtained from the American Type Culture Collection (ATCC; 
Manassas, Virginia) and the same procedure for EPEC was followed. 
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Prebiotics and Plant Extracts 
Cranberry.   Cranberry concentrate was obtained from Ocean Spray 
Cranberries, Inc. The concentrate was used directly as concentrated material 
following neutralization with 1M NaOH.  The total solids concentration was 
determined on a dry weight basis.  The cranberry concentrate was also 
fractionated by dialysis to yield a high molecular weight component (HMW).  
Exhaustively dialysis was performed for 5 days at 4°C using 12,000 – 14,000 
MW cut-off dialysis tubing against distilled water. The non-dialyzable material 
was then freeze dried. A stock solution was prepared by resuspending the freeze 
dried material in distilled water to a concentration of 10 mg/ml. The solution was 
filter sterilized using 0.22-µm filters.  
Chitin Oligosaccharides (COS).  Different COS fractions (based on MW) were 
obtained from Berit Bjugan Aam (Norwegian University of Life Science, Norway), 
as freeze dried powders. Freeze dried material was resuspended in autoclaved 
distilled water and final concentration of the stock solution was determined for 
each fraction.  
Konjac Mannan (MOSk).  Konjac mannan was obtained from Wayne Muller 
(United States Army NSRDEC, Natick, MA) as a dry powder. MOSk was 
prepared as a concentrated stock solution with distilled water at a final 
concentration of 160 mg/ml. The solution was filter sterilized using 0.22-µm 
filters.  
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Yeast Mannan (MOSy) Yeast mannan was obtained from Lallemand (Ontario, 
Canada) as a powdered material. A stock solution was prepared dissolving 160 
mg of powder per ml of distilled water. The solution was centrifuged at 201 x g for 
10 minutes and the supernatant was saved.  The supernatant was filtered 
through a 0.4-µm filter and subsequently freeze dried.  A stock solution was 
prepared in distilled water at a final concentration of 200 mg/ml. 
Tissue culture cells HEp-2 cells were obtained from ATCC.  Cells were grown 
in 75 cm2 tissue culture flasks (Corning) containing 25 ml of MEM supplemented 
with 10% FBS in a CO2 incubator at tissue culture conditions.  Confluent Hep-2 
cells were harvested by adding 0.5 ml of 0.25% Trypsin-EDTA Solution (Sigma) 
and incubating for 15 minutes at tissue culture conditions.  Trypsin was 
inactivated with 0.5 ml of FBS. Cells were then seeded onto 12-mm diameter 
glass coverslips in 24-well tissue culture plates (Falcon) at approximately 3.6 x 
105 viable cells per well, and 500 µl of MEM supplemented with 10% FBS was 
added to each well.  Plates were incubated under tissue culture conditions for 30 
hours prior to the start of each experiment, or until confluency was reached. 
Adherence Assays Cell suspensions of EPEC E2348/69 (O127:H6), Salmonella 
enterica serovar Typhimurium, and EHEC were prepared as described above. 
Prebiotics were mixed with bacterial cultures (in MEM supplemented with FBS) 
prior to addition to the tissue culture cells. As a control, water was added to the 
bacterial cultures at the same volume as the prebiotics. The prebiotic solutions 
were prepared at different concentrations depending on the product used. The 
plates were incubated for 30 minutes for EPEC E2348/69 (O127:H6) and 
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Salmonella enterica serovar Typhimurium, and 90 minutes for EHEC. The wells 
were then washed 5 times with PBS to remove non-adhered bacterial cells. 
Experiments were done in duplicate and replicated 3 times (n=6) for analysis with 
quantitative real time PCR (qRT-PCR) and 2 times for microscopic analyses 
(n=4). 
Quantitative Real Time PCR (qRT-PCR).   Bacterial cells from adherence 
assays were detached by the addition of 1 ml of 0.1% Triton X-100 for 30 
minutes at room temperature. Bacterial cells were harvested and centrifuged for 
5 min at 10,000 x g, supernatant was discarded and pellet was resuspended in 
180 µl of buffer ATL from the DNeasy Blood and Tissue Kit (Qiagen, Hilden, 
Germany).  Instructions provided in the manufacturer’s manual for DNA 
extraction of Gram negative bacteria were followed to complete the extraction.  
 Quantitative real time PCR (qRT-PCR) was performed using a Mastercycler 
Realplex2 (Eppendorf AG, Hamburg, Germany). Each PCR was done in a 25 µl 
volume. The reaction mixture comprised 11.25 µl of the 20x SYBR solution and 
2.5-µl Real-MasterMix (5Prime), 0.5 µM of each primer, and 1 µl of DNA 
template. (Martínez et al. 2009) Specific primers and amplification program were 
followed for each organism.  
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Table 1. Primers and PCR programs for the different organisms used in this 
study. 
Table 1.   
Organism Primers (5’ -  3’) Amplification Program 
EPEC and 
EHEC 
eaeFor  GGCGATTACGCGAAAGATAC 
eaeRev GATTAACCTATGCCGTTCCA 
Initial denaturation at 95°C for 10 
min and 40 cycles at 95°C for 15s 
and 62°C for 1 min for annealing 
and extension.  
Salmonella  139 -GTGAAATTATCGCCACGTTCGGGCAA 
141 -TCATCGCACCGTCAAAGGAACC 
Initial denaturation at 94°C for 2 
min and 45 cycles at 94°C for 20s 
and 62°C for 1 min for annealing 
and extension 
 
Microscopic enumeration Adhered cells were fixed with 100% methanol for 20 
minutes and stained with 10% Geimsa for 15 minutes.  The slides were then 
washed once with sterile distilled water and dried overnight at room temperature.  
Coverslips were mounted on microscope slides and observed under a phase 
contrast microscope with the 100x objective. Fifteen pictures of each coverslip 
were taken using Motic Image software following a pre-established pattern 
throughout the entire coverslip.  The number of cells and bacteria in each picture 
were counted using Image J image analysis software.  Total adherence was 
calculated as the number of adhered bacteria per tissue culture cell.  Adherence 
inhibition was calculated as the number of adhered bacteria per cell in the control 
minus the number of adhered bacteria per cell in the treatment divided by the 
number of adhered bacteria per cell in the control. 
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Statistical analysis Significant differences between the treatments were 
determined by one way analysis of variance (ANOVA)  using Tukey to compare 
all pairs of columns with alpha = 0.05. GrpahPad Prism5 software was used to 
perform statistical analysis.  
Results 
Cranberry concentrate reduces adherence of EPEC and Salmonella 
Typhimurium to HEp-2 cells.  Adherence of EPEC and Salmonella typhimurium 
in the presence and absence of a neutralized cranberry concentrate to HEp-2 
cells was measured by qRT-PCR (Figure 2).  Experiments revealed that the 
neutralized cranberry concentrate inhibited adherence of EPEC and S. 
typhimurium at a minimum concentration of 25 and 10 mg/ml, respectively.  
Cranberry High Molecular Weight Component reduces adherence of EPEC, 
EHEC, and Salmonella Typhimurium to HEp-2 cells.  Adherence of EPEC, 
EHEC and Salmonella Typhimurium in the presence and absence of a cranberry 
HMW component to HEp-2 cells was measured by qRT-PCR and by microscopic 
enumeration (Figure 1).  Both methods revealed that the HMW component of 
cranberry inhibits adherence of EPEC (A,B), Salmonella typhimurium (C, D), and 
EHEC. (E, F) 
COS inhibits adherence of EPEC to HEp-2 cells.  Adherence of EPEC in the 
presence and absence of different fractions of chitin oligosaccharides to HEp-2 
cells was measured by microscopic examination (Figure 3).  At a concentration of 
16 mg/ml, COS fraction KN + C88 (A) inhibited adherence by 93%, fraction 
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W275A (C) reduced adherence by 72%, FA 0.15(NC) reduced adherence by 
76% and fraction FA 0.61 reduced adherence by 74%. 
MOSk does not inhibit adherence of EPEC, EHEC, and Salmonella 
Typhimurium to HEp-2 cells.  Adherence of EPEC, EHEC, and Salmonella 
typhimurium in the presence and absence of MOSk to HEp-2 cells was 
measured by qRT-PCR  and microscopic counting  (Figure 4). Both methods 
revealed there was no inhibition of EPEC, EHEC, or Salmonella typhimurium by 
MOSk.  
MOSy inhibits adherence of EPEC and Salmonella Typhimurium to HEp-2 
cells. Adherence of EPEC, EHEC and Salmonella typhimurium in the presence 
and absence of MOSy to HEp-2 cells was measured by qRT-PCR and 
microscopic examination (Figure 5). Both methods revealed that MOSy inhibits 
adherence of EPEC and Salmonella typhimurium. Results show no significant 
reduction in adherence of EHEC to HEp-2 cells. 
Discussion  
The use of molecular decoys to prevent pathogen adherence was 
proposed more than a decade ago (Ebrahim 1997; Andersson et al. 1986; 
Cravioto et al. 1991; Ofek et al. 1978). In recent years, several oligosaccharides, 
including food and non-food grade materials, have been tested for their anti-
adherence effects against different pathogens.   Extracts from plants and other 
naturals sources have also been studied for their anti-adherence activities.  In 
this report, we compared five different novel oligosaccharides and plant extracts 
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for their ability to prevent or inhibit adherence of EPEC, EHEC, and S. 
typhimurium to the surface of epithelial cells.  The results showed that while 
some of the test materials were very effective, other agents had little ability to 
inhibit adherence. 
Cranberry juice consumption has long been promoted for its putative 
therapeutic activities, and especially for preventing or treating urinary tract 
infections (Schaeffer 2004). It was reported that the maximum adherence 
inhibition of Helicobacter pylori to gastric mucus was at a concentration of 1 
mg/ml (Burger et al. 2000).  Similarly, it was also reported that cranberry juice 
cocktail reduced adherence of E. coli isolates from patients with UTI by more 
than 75% (Sobota 1984). The mechanism by which cranberry inhibits adhesion is 
poorly understood, although it has been reported that the high molecular weight 
component might directly interact with P-fimbriae by altering the latter’s 
conformation and also by binding hydrophilic components (Y. Liu et al. 2006).  
Our results when using neutralized cranberry concentrate and the HMW 
component show inhibition of enteric pathogens such as Salmonella 
typhimurium, EPEC and EHEC to intestinal epithelial cells. These results suggest 
that consumption of cranberry juice might be helpful in preventing infections 
caused by the latter organisms.  
Chitosan derivatives have several applications in the food industry, and 
one of the most important properties is their antimicrobial activity; (Xia et al. 
2011; Tsai et al. 2002) the latter has been reported to be, to a certain extent, by 
inhibiting bacterial adherence. (Rhoades et al. 2006; Xia et al. 2011) Four 
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different fractions of chitin oligosaccharides were tested in this study; they all 
showed bacterial adherence inhibition higher than 70%.  Growth of the organism 
in TSB with COS at the same concentration was also measured to determine if 
COS had a general bactericidal effect; no inhibition was observed (data not 
shown).  Thus, COS appears to have significant antiadherent activity, although 
further research is needed to establish how stable and safe this material is before 
it could be added as a food ingredient.  
Mannan from konjac root did not inhibit adherence of any of the organisms 
studied. Bacterial adherence can be mediated by specific proteins present in the 
surface of bacteria, which recognize specific receptors on the surface of epithelial 
cells. (Bavington et al. 2005; Klemm et al. 2010; Sharon 2006) The specificity of 
these lectin-like adhesins depends greatly on the bacterial species and may vary 
greatly among organisms, even among bacterial strains. For this reason, not all 
the proposed oligosaccharides or plant extracts will necessarily inhibit pathogen 
adherence to the surface of epithelial cells.  
Mannan oligosaccharides (MOS) from yeast cell walls have been shown 
to be important in the reduction of pathogen colonization (K. Newman et al. 
1994). Many gram-negative bacteria attach to the surface of epithelial cells via 
mannose-specific fimbriae (Ofek et al. 1977); MOS can act as a molecular decoy 
to inhibit adherence of these pathogens to epithelial cells. Spring et al. 2000 
reported that multiple strains of Salmonella and Escherichia coli agglutinated 
MOS in vitro. In this study, mannan obtained from the cell wall of yeast showed 
inhibition of different bacterial strains to epithelial cells.  
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Conclusions 
Collectively, our results showed that different oligosaccharides and plant 
extracts reduce adherence of Escherichia coli and Salmonella typhimurium in 
tissue culture cells.  However, not all of the oligosaccharides tested were 
effective in reducing adherence, suggesting that binding inhibition depends on 
the adherence mechanism of the organism and the specific structure of the 
oligosaccharide. Further research is needed to determine whether the 
compounds tested can be food grade and if the concentration at which they 
inhibit is within the economic and functional ranges suitable for food products.  
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Figure 1. Adherence of EPEC, EHEC, and Salmonella typhimurium  to HEp-2 
cells in the presence of a cranberry HMW component  (0, 0.2, 0.4, 0.8, 1, and 2 
mg/ml) analyzed by qRT-PCR (n=6) (A, C) and microscopic counting (n=4) (B, D, 
F). Statistically significant effects are indicated by an asterisk. 
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Figure 2. Adherence of EPEC and Salmonella typhimurium to HEp-2 cells in the 
presence of a neutralized cranberry concentrate analyzed by qRT-PCR (n=6). 
Statistically significant effects are indicated by an asterisk. 
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Figure 3. Adherence of EPEC to HEp-2 cells in the presence of COS analyzed 
by microscopic enumeration. (n=6) Statistically significant effects are indicated by 
an asterisk. 
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Figure 4. Adherence of EPEC, EHEC, and Salmonella typhimurium to HEp-2 
cells in the presence of MOSk analyzed by qRT-PCR (n=6) (A, C, D) and 
microscopic counting (n=4) (B). Statistically significant effects are indicated by an 
asterisk. 
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Figure 5. Adherence of EPEC, EHEC, and Salmonella typhimurium to HEp-2 
cells in the presence of MOSy by qRT-PCR (A, C, D) (n=6) and microscopic 
counting (B) (n=4). Statistically significant effects are indicated by an asterisk. 
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Chapter 4 
Lactoferrin as an anti-adherent agent: Inhibition of Cronobacter sakazakii 
adherence to epithelial cells 
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Abstract 
Cronobacter sakazakii is now recognized as an opportunistic pathogen and has 
been implicated in rare but severe cases of NEC, meningitis, and sepsis in 
neonates. The first step in bacterial pathogenesis requires the organism to 
adhere to host cells surfaces; therefore, agents that inhibit adhesion might be 
useful for preventing infections. Lactoferrin, an iron binding protein found in milk, 
has been shown to inhibit bacterial adherence by direct interaction and disruption 
of bacterial surfaces. Therefore, the goal of this research was to assess the 
ability of two different types of lactoferrin to inhibit adherence of Cronobacter 
sakazakii to a HEp-2 human cell line.  Results showed that the adherence of C. 
sakazakii was significantly reduced at a minimum concentration of 10 mg/ml.  
However, at higher concentrations (up to 50 mg/ml), further reductions in 
adherence were not observed. These results suggest that lactoferrin might 
interact with C. sakazakii and directly inhibit adhesion to tissue culture cells.  
Introduction 
Lactoferrin (Lf) is an 80 kDa iron binding glycoprotein, belonging to the 
transferrin family. It is found in high concentrations, up to to 7 g/L in human 
colostrum (Actor et al. 2009) and up to 1.5 mg/ml in bovine colostrum (Yekta et 
al. 2010). It is also present in fluids of the digestive tract (Giugliano et al. 1995; 
Legrand et al. 2005). The concentration of lactoferrin in milk varies over time and 
is dependent on the stage of lactation (Farnaud 2003). 
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Several biological functions have been attributed to lactoferrin.  It has 
bactericidal and bacteriostatic properties, as well as anti-inflammatory and 
immunomodulatory activities, based on both in-vitro and in-vivo models (Gomez 
et al. 2003). In particular, lactoferrin is known for its antimicrobial activity, for 
which at least two different mechanisms have been proposed.  The first model is 
based on the ability of LF to bind iron, hence depriving pathogens from essential 
nutrients and thereby inhibiting their growth (Farnaud 2003; Jenssen et al. 2009). 
This antimicrobial activity is reduced upon iron saturation of the molecule, 
suggesting that LF is bacteriostatic rather than bactericidal (Farnaud 2003; 
Arnold et al. 1980; Kalmar et al. 1988; Yamauchi et al. 1993; Valenti et al. 2005).  
A second means by which LF exhibits antimicrobial activity is via an iron-
independent mechanism.  According to this model, LF inhibits bacterial 
pathogens by a direct interaction mediated by binding of the Lipid A portion of the 
lipopolysaccharide (LPS) of Gram negative bacteria (Appelmelk et al. 1994; 
Brandenburg et al. 2001; Shahriar et al. 2006). This then leads to the disruption 
of the bacterial membrane and results in the release of LPS (Ellison et al. 1988; 
Appelmelk et al. 1994; Brandenburg et al. 2001).  
 There is now evidence that lactoferrin can also inhibit bacterial adherence 
to host cell surfaces, which is the first step for bacterial pathogenesis. It is well 
known that many enteric pathogens, including enteropathogenic E. coli (EPEC), 
adhere to and infect host cells via a Type III secretion system.  By blocking the 
initial step of EPEC attachment to host cells, the actin polymerization step of the 
TTSS cascade is impaired (Ochoa et al. 2003).  Other investigations (Qiu 1998) 
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demonstrated that human lactoferrin also has proteolytic activity, hence providing 
an additional mechanism by which it can exhibit anti-adherent activity (Valenti et 
al. 2005). In addition, it was also reported (Yekta et al. 2010) that lactoferrin 
inhibits adherence of E. coli O157:H7 to Caco-2 cells in a dose dependant 
manner, mainly due to disruption of the Type III Secretory System. 
In addition to its anti-adherence role, Lactoferrin has been identified as a critical 
component for mediating immune responses. It reduces oxidative stress, thus 
controlling excess inflammatory response (Actor et al. 2009). It may limit the 
inflammation caused by bacterial infections, which can lead to prevention of 
septic shock (Legrand et al. 2008). Along with its anti-inflammatory properties, it 
is involved in many events related to immune responses, such as modulation for 
cytokine production, chemokine recognition and lymphocyte migration (Actor et 
al. 2009). 
Cronobacter sakazakii is now considered an opportunistic pathogen that 
has been implicated in bacteremia, necrotizing enterocolitis (NEC), and neonatal 
meningitis (Healy et al. 2010).  Although C. sakazakii infections are more 
common in neonates and premature babies, it has been reported that immune 
compromised adults are also susceptible to infections caused by this bacterium 
(Healy et al. 2010). The infant mortality rate associated with C. sakazakii 
infections ranges from 40 to 80% (Bowen et al. 2006). In addition, survivors often 
develop serious long-term neurological complications (Lai 2001). Despite the 
relatively low incidence of disease, the severity of these diseases has led to 
considerable interest in developing strategies for preventing or mitigating 
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infections.  Therefore, the main goal of this research was to assess the ability of 
lactoferrin to inhibit adherence of C. sakazakii to a human cell line. 
Materials and Methods 
Organisms and growth conditions. Strains of C. sakazakii used in this study 
were obtained from K. Venkitanarayanan (Department of Animal Science, 
University of Connecticut) and conditions for their growth have been previously 
described(Quintero et al. 2011).  Briefly, frozen stock cultures of each organism 
were thawed, plated onto Tryptic Soy Agar (TSA; Difco) and grown overnight at 
37°C.  A single colony was inoculated into 10 ml of Tryptic Soy Broth (TSB; 
Difco) and incubated aerobically, without shaking.  Preliminary experiments 
revealed that adherence rates were highest when cells were in late log phase.  
Therefore, a 1% inoculum was incubated for 4 hours at 37°C without shaking. 
Cultures were harvested by centrifugation (3,184 x g for 8 minutes), washed 
once with phosphate-buffered saline (PBS) and re-suspended in minimal 
essential medium (MEM; Hyclone, Logan, Utah), supplemented with 10% fetal 
bovine serum (FBS; Hyclone).  Minimal essential medium was pre-equilibrated at 
tissue culture conditions (5% CO2, 95% relative humidity, 37°C).  Based on 
additional preliminary experiments, strain 4603 repeatedly gave the high 
adherence rates on HEp-2 cells and was used for all subsequent experiments. 
Lactoferrin.  Two different types of lactoferrin (003 and 004) were obtained from 
Mead Johnson Nutrition (Evansville, IN). The lactoferrin was prepared as 
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concentrated stock solutions with distilled sterile water at a final concentration of 
100 mg/ml.  The solutions were filter sterilized using 0.22 µm filters.  
Tissue culture cells.  HEp-2 cells were obtained from the American Type 
Culture Collection (ATCC; Manassas, Virginia).  Cells were grown in 75 cm2 
tissue culture flasks (Corning) containing 25 ml of MEM supplemented with 10% 
FBS in a CO2 incubator at tissue culture conditions.  Confluent Hep-2 cells were 
harvested by adding 0.5 ml of 0.25% Trypsin-EDTA Solution (Sigma) and 
incubating for 15 minutes at tissue culture conditions.  Trypsin was inactivated 
with 0.5 ml of FBS. Cells were then seeded onto 12-mm diameter glass 
coverslips in 24-well tissue culture plates (Falcon) at approximately 3.6 x 105 
viable cells per well, and 500 µl of MEM supplemented with 10% FBS was added 
to each well.  Plates were incubated under tissue culture conditions 30 hours 
prior to the start of each experiment, or until confluency was reached. 
Adherence Assays. Cell suspensions of C. sakazakii 4603 for HEp-2 cells were 
prepared as described above.  Lactoferrin was mixed with bacterial cultures (in 
MEM supplemented with FBS) prior to addition to the tissue culture cells.  The 
plates were incubated for 30 minutes at tissue culture conditions. Preliminary 
experiments indicated that 30 minutes of incubation were optimal for adherence 
of the bacterial strains to the HEp-2 tissue culture.   
Quantitative Real Time PCR (qRT-PCR).   Bacterial cells from adherence 
assays were detached by the addition of 1 ml of 0.1% Triton X-100 for 30 
minutes at room temperature. Bacterial cells were harvested and centrifuged for 
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5 min at 10,000 x g, supernatant was discarded and pellet was resuspended in 
180 µl of buffer ATL from the DNeasy Blood and Tissue Kit (Qiagen, Hilden, 
Germany).  Instructions provided in the manufacturer’s manual for DNA 
extraction of Gram negative bacteria were followed to complete the extraction.  
Quantitative real time PCR (qRT-PCR) was performed using a Mastercycler 
Realplex2 (Eppendorf AG, Hamburg, Germany). Each PCR was done in a 25 µl 
volume. The reaction mixture comprised 11.25 µl of the 20x SYBR solution and 
2.5-µl Real-MasterMix (5Prime), 0.5 µM of each primer, and 1µl of DNA template 
(Martínez et al. 2009). Specific primers and amplification program were followed 
for each organism. (Table 1) 
Results 
Lactoferrin 003 inhibits adherence of C. sakazakii to HEp-2 cells. Adherence 
of C. sakazakii 4603 in the presence and absence of lactoferrin 003 was 
measured by qRT-PCR. Initial doses ranged from 0.1 to 1.0 mg/ml.  However, no 
inhibition was observed at these concentrations (data not shown).  Subsequently, 
doses of 2 to 50 mg/ml were tested. Adherence inhibition was observed at a 
minimum concentration of 10 mg/ml.  Higher concentrations, however, did not 
show a further antiadhesive effect (Figure 1). 
Lactoferrin 004 inhibits adherence of C. sakazakii to HEp-2 cells. Adherence 
of C. sakazakii 4603 in the presence and absence of lactoferrin 004 was 
performed as for lactoferrin 003.   As before, adherence inhibition was observed 
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at a minimum concentration of 10 mg/ml and higher concentrations had no 
additional effect (Figure 2). 
Discussion 
Among the biological functions attributed to lactoferrin are antimicrobial, 
anti-inflammatory, and immunomodulatory activities (Kruzel et al. 2002; Legrand 
et al. 2008; Actor et al. 2009; Brock 2002; Ward et al. 2002). The mechanisms 
that account for the antimicrobial properties have been reported to be iron 
dependent and independent (Bullen et al. 1972; Arnold et al. 1980; Orsi 2004; 
Dalmastri et al. 1988; Bortner et al. 1989); the latter implying direct interaction of 
lactoferrin with  the bacterial cell surface (Appelmelk et al. 1994; Brandenburg et 
al. 2001; Shahriar et al. 2006). This direct interaction can result in the inability of 
the bacterium to adhere to host cell surfaces (Qiu 1998; Jenssen et al. 2009; 
Ochoa et al. 2003; DeVinney et al. 1999; Goosney et al. 1999). Previous studies 
have shown that lactoferrin prevents colonization of Haemophilus influenzae, 
degrades virulence proteins secreted by Shigella flexeneri, and inhibits 
adherence of Salmonella typhimurium, as well as it interferes with the Type III 
Secretory System present in many pathogenic bacteria (Qiu 1998; Jenssen et al. 
2009; Gomez et al. 2003; DeVinney et al. 1999; Goosney et al. 1999; Gomez et 
al. 2001; Ochoa et al. 2003; Bessler et al. 2006).  
Our results show that two different types of lactoferrin inhibit adherence of 
Cronobacter sakazakii 4603. The mechanism by which C. sakazakii adheres to 
host cell surfaces has not been well studied, although it has been established 
120 
 
that an outer membrane protein A (OmpA) might play an important role in the 
attachment and invasion of Caco-2 cells (Kim et al. 2008). The mechanism by 
which lactoferrin inhibits adherence of C. sakazakii to HEp-2 cells requires further 
investigation to determine whether it is strictly dependent on direct interaction of 
lactoferrin with the bacterial cell surface. Interestingly, lactoferrin inhibits C. 
sakazakii 4603 at a minimum required concentration of 10 mg/ml, although 
inhibition does not increase significantly by further increasing the lactoferrin dose. 
This suggests that lactoferrin may directly interact with the bacterial surface of 
Cronobacter sakazakii, as a mechanism to inhibit its adherence to epithelial cells. 
Therefore, upon saturation, there will not be a greater antiadherent effect with 
higher lactoferrin concentrations.  
Conclusion 
Altogether, our results show that lactoferrin 003 and lactoferrin 004 inhibit 
adherence of Cronobacter sakazakii 4603 to HEp-2 cells. Although the minimum 
concentration to inhibit adherence was found to be 10 mg/ml, further research is 
needed to establish the means by which lactoferrin interacts with C. sakazakii to 
inhibit its adherence.  
The first, and a crucial step in bacterial pathogenesis, is bacterial adhesion to 
host cell surfaces. Agents that inhibit pathogen adherence, such as lactoferrin, 
may be considered as food ingredients that might serve as a prophylactic 
treatment to prevent infections.  
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Figure 1. Adherence of Cronobacter sakazakii 4603 to HEp-2 cells in the 
presence of Lactoferrin 003 at doses ranging from 0 to 50 mg/ml. Statistically 
significant effects are indicated by an asterisk. 
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Figure 2. Adherence of Cronobacter sakazakii 4603 to HEp-2 cells in the 
presence of Lactoferrin 004 at doses ranging from 0 to 50 mg/ml. Statistically 
significant effects are indicated by an asterisk. 
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Table 1. Primers and qRT-PCR program 
Table 1.   
Organism Primers (5’ -  3’) Amplification Program 
C. sakazakii For  TATAGGTTGTCTGCGAAAGCG 
Rev GTCTTCGTGTGCGAGTTTG 
denaturation at 95°C for 10 s, 45 
cycles consisted of denaturation at 
95°C for 5 s, 62°C for 20 s for 
annealing and extension. 
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Chapter 5 
Conclusion 
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In this research we established that several food-grade prebiotic carbohydrates, 
plant extracts, and other naturally-derived molecules inhibit adherence of enteric 
pathogens to epithelial cells. Specifically, GOS and PDX, alone and in 
combination, as well as lactoferrin inhibit adherence of Cronobacter sakazakii to 
a HEp-2 cell line. Furthermore, it was determined that a high molecular weight 
component from cranberry, mannan from yeast, and chitin oligosaccharides, 
inhibit adherence of EPEC, EHEC, and Salmonella typhimurium to epithelial 
cells. The major findings of this research are described below. 
• GOS and a blend of GOS-PDX effectively reduce adherence of C. 
sakazakii in tissue culture experiments. 
• There is enough similarity between GOS and human milk 
oligosaccharides to be effective in inhibiting adherence at the 
concentration used in this study. 
• The antiadherent effect of prebiotic oligosaccharides varies among 
different strains and epithelial cell lines. 
• Different oligosaccharides and plant extracts inhibit adherence of EPEC, 
EHEC, and Salmonella typhimurium to tissue culture cells.  
• The high molecular weight component of cranberry inhibits adherence of 
the three enteric pathogens used in this study, at concentrations ranging 
from 0.2 to 2 mg/ml. 
• Mannan from yeast cells inhibits adherence of EPEC and Salmonella 
typhimurium at a minimum concentration of 75 and 10 mg/ml, respectively. 
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• Mannan from konjac root does not inhibit adherence of any of the tested 
enteric pathogens. 
• Different fractions of chitin oligosaccharides reduce adherence of EPEC to 
a HEp-2 cell line. Reduction in adherence is mainly due to adherence 
inhibition rather than by a bactericidal effect. 
• Lactoferrin inhibits adherence of Cronobacter sakazakii to a human 
epithelial cell line, 
• The minimum lactoferrin concentration required for C. sakazakii 
adherence inhibition is 10 mg/ml; higher concentrations do not exhibit 
higher adherence inhibition. 
• Collectively, these results provide a basis for development of natural 
prophylactic agents that may be effective at reducing or preventing 
infections by enteric pathogens. 
• In addition, the results of this research suggests that food-grade anti-
adherent agents may serve as a substitute for the widespread use of 
antibiotics whose use in animal agriculture may soon be restricted. 
 
 
